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Rheumatoid Arthritis (RA) is a systemic disease that is mainly characterised by 
symmetric erosive synovitis and occasional multisystem involvement. Most patients 
exhibit a chronic fluctuating course of disease that, if left untreated, results in progressive 
joint destruction, deformity, disability and premature death. It frequently affects patients 
in their most productive years, and thus, disability results in a major economic loss [1]. 
The progressive joint destruction is the most prominent feature of RA, and is now 
regarded as the result from the interaction of synovial hyperplasia, chronic inflammation, 
and autoimmunity [2,3]. However, the precise etiology of RA is still unclear.
Important developments in the last decade influenced the management of RA. Mainly for 
biological and immunological reasons, it was recognised that a progressive inflammatory 
disease as RA should be treated with disease modifying anti-rheumatic drugs (DMARDs) 
as early as possible after disease onset [4]. The availability of more effective DMARDs, 
use of combination therapies in additive, saw-tooth or step-down schemes, and the 
introduction of new "biological” agents opened new treatment options. For the first time, it 
was possible to reach relatively large treatment effects in time spans of 3-6 months, and 
even to induce remission [5]. Instruments for assessing process and outcomes of RA 
were developed, while standardised use for clinical trials, cohort studies and clinical 
practice was promoted [6-8]. This made it possible to assess the effects of RA therapy 
more closely, and made outcome assessment in reach of daily clinical practice [9].
In the management of RA, there is now general agreement that rheumatoid inflammation 
must be controlled as soon as possible, as completely as possible, and that this control 
should be maintained for as long as possible, consistent with patient safety [5]. Further, 
more attention is paid to the integration of outcome assessment in the management of 
RA. To support the management of RA, the Swiss Clinical Quality Management in 
Rheumatoid Arthritis (SCQM) was established in 1997 [10]. Core activity of the SCQM is 
to provide rheumatologists with a measurement-feedback system to monitor the course 
of RA. Using the feedback, drug therapy can be optimised to reduce disease activity, 
leading to prevention of joint damage and concurring disability.
The main subject of this thesis is to study if measurement-feedback, or decision support, 
is effective in the management of RA.
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Monitoring and documentation of rheumatoid inflammation is not used regularly in daily 
clinical practice [11-13]. 'Many, if not most, clinicians feel it is not necessary to document 
obvious clinical improvement recognised by both the patient and the clinician. A positive 
response to the question "How are you doing?” is sufficient' [14]. In Chapter 2, it is 
argued that, to evaluate if treatment goals are reached and to support adaptation of the 
treatment program, the management of RA patients in daily clinical practice should 
include systematic and regular evaluation of rheumatoid inflammation.
The major practical problem in monitoring is: how does a clinician know when 
rheumatoid inflammation is optimally controlled?; what are the criteria to state that 
inflammatory activity is under control? The disease activity score (DAS) and the EULAR 
response criteria are suited to aid in determining and evaluating actual status and 
change in status [15-17], particularly when applied to individual patients with RA. The 
reason is, that the response status according to the EULAR criteria is not only dependent 
on the magnitude of change, as with the ACR response criteria [18], but also depends on 
the absolute level of inflammatory activity reached. A low level of inflammatory activity 
over time reduces the probability of progression of radiological visible joint damage [19]. 
With the help of regular monitoring of the DAS, rheumatoid inflammation can be 
controlled by "titration” of the DMARD dose. The principle of dose titration was 
demonstrated in 2 studies in RA, using a step-up and a step-down scheme, respectively 
[20,21].
In Chapter 3, the use of a monitoring system, the Swiss Clinical Quality Management in 
Rheumatoid Arthritis (SCQM), for daily clinical practice is demonstrated in 4 RA patients. 
Management aimed at reduction of inflammatory activity and pain in the short-term, and 
joint damage, and consequently disability, in the long-term.
The advantages of the use of graphical display of clinical status and disease scores for 
decision support and improving compliance are illustrated. Also, it is demonstrated that 
there is a need to be cautious when using indices such as the DAS for individual 
patients. Most measures are developed based on more or less homogeneous groups of 
patients. A measure is most likely to be valid for an individual, if that patient represents 
sufficient characteristics of such a group.
As analogue or complement to the assessment of RA disease activity with the DAS, the 
patient assessed Rheumatoid Arthritis Disease Activity Index (RADAI) has been 
developed [22]. The aim of the RADAI is to provide an easy to use assessment of RA
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disease activity, which serves as a complement to the physician’s assessments, with 
which the physician's assessment could be omitted in certain situations. The RADAI is 
used in the monitoring system of the SCQM (Chapter 3), and as the primary outcome 
measure in a controlled clinial trial on the effects of the monitoring system on disease 
activity (Chapter 6). In Chapter 4, it is described how a cross-sectional sample of 584 
RA out-patients was used to assess the internal consistency and the convergent validity 
of the RADAI. It was shown that the single index approach is valid, and that the RADAI 
as measure of patient perceived disease activity is related with, but may not 
automatically replace, other measures of disease activity such as the DAS28.
While it was shown that the RADAI is a valid measure of disease activity cross- 
sectionally, its responsiveness, or ability to capture clinically important changes, was still 
unknown. Measures that are cross-sectionally valid are not necessarily responsive [23]. 
In Chapter 5, a post-hoc analysis of data from a randomized double blind controlled trial 
of MTX versus Collagen II [24] provided evidence that the RADAI is sensitive to detect 
relevant increases in disease activity in patients with RA. The changes in the RADAI 
were well correlated with changes in the DAS28. The discriminative ability of the RADAI 
and of the DAS28 to detect a flare, reflected by the area under the ROC curve, were 
virtually the same, as were the effect sizes. Thus, there is evidence that the RADAI can 
capture relevant increases in RA disease activity.
The main reason to implement a measurement-feedback system in daily clinical practice 
is, that it could help to adjust the treatment strategy for individual RA patients for 
achieving optimal control of disease activity. In Chapter 6, a controlled clinical trial with 
48 rheumatologists and 264 patients is described, to study whether measurement- 
feedback is effective. Afterwards, the sample appeared to comprise users and non-users 
of the feedback system. Use was associated with a reduction of disease activity in the 
feedback period as compared to the control period, in patients with high disease activity 
at baseline. However, how far changes in medication strategy played a role remained 
uncertain. Further, there were no explicit guidelines on the management of RA provided. 
It is possible that the combination of systematic monitoring with explicit guidelines is an 
adequate tool to promote changes in medication strategy.
In Chapter 7, the influence of guideline adherence on outcome was studied by post-hoc 
analysis of a 48-week, randomised, double blind and placebo controlled trial, on the
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effect of suppletion of folic or folinic acid on toxicity and efficacy of MTX treatment in RA
[20]. The MTX dose was steadily increased according to the level of disease activity, 
using a guideline comparable to the EULAR criteria [16]. However, the rheumatologists 
were allowed to deviate from the guideline. It appeared that adherence to the guideline 
for MTX dosing had an influence on drug dose and efficacy. Prescribing a MTX dose 
lower than the guidelines proposed reduced efficacy, and had no clear beneficial effect 
on toxicity. The effect of prescribing doses higher than the guidelines proposed is 
unclear, but it did not seem to be more beneficial. The study was not comparing the use 
of guidelines versus no guidelines. Thus, it can not be stated that guidelines will be 
effective in clinical practice. However, as it can be expected that in clinical practice the 
variation in prescribing MTX dose is much larger, guidelines with appropriate adherence 
may influence efficacy, and perhaps toxicity, in practice.
For reasons of efficiency, it is important that a measurement-feedback system is feasible 
in daily clinical practice, and is appreciated by its users. Further, it is useless to study the 
efficacy of decision support if compliance is low, especially if the study outcome depends 
heavily on patient health outcomes. In Chapter 8, a survey is described, performed to 
assess rheumatologists’ opinion about feasibility of the measurement-feedback system in 
RA. In addition, it could be analysed whether motivational aspects play a role in 
perception and use of the measurement-feedback system.
Rheumatologists joining the measurement-feedback system for the evaluation of their 
individual RA patients ("internal motivation”) were more satisfied with the system than 
rheumatologists joining because of scientific purposes or as obligation ("external 
motivation”). Further, rheumatologists with "internal motivation” perceived the 
measurement-feedback system as more useful, were more satisfied with the feedback 
report, less bothered by the time consumption, and also made more use of it. Most 
important barriers concerned the practical use for decision-making, lag time of the 
feedback, and time consumption. Influencing motivation and specific reduction of effort 
might increase overall acceptance and use of the measurement-feedback system for 
decision support.
The combination of clinical guidelines and systematic evaluation could be a valuable 
decision support in optimizing the management of RA patients. However, the efficacy of 
decision support in the management of RA remains unproven. In Chapter 9, a proposal 
is made for design and analysis of a randomized controlled trial on the efficacy of a
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decision support system on physician performance and health outcomes in the 
management of RA.
A decision support intervention primarily aims at the physician. Therefore, a cluster 
randomized controlled trial, where physicians are randomized rather than patients, is the 
most appropriate design. Using the proportion of patients with a low inflammatory activity 
(DAS28 < 3.2) as primary outcome, it was estimated that a sample size of 238 RA 
patients and 22 rheumatologists would be needed, which is 2.5 times larger than when 
clustering is ignored. Analysis can be performed with Multilevel Analysis, which is a 
complex technique but has the advantage that it deals with multiple variables and 
produces estimators for the strength of effects [25]. To prevent bias in this particular 
design, patient recruitment has to take place before randomisation, the control 
intervention has to be carefully designed, the primary outcome has to be measured by 
independent asessors, and drop-outs should be prevented as much as possible.
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Chapter 2
The merits of monitoring: 
Should we follow all our RA patients in daily practice?
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Rheumatoid Arthritis (RA) is mainly characterised by symmetric erosive synovitis and 
occasional multisystem involvement. Most patients exhibit a chronic fluctuating course of 
disease that, if left untreated, results in progressive joint destruction, deformity, disability 
and premature death. It frequently affects patients in their most productive years, and 
thus, disability results in a major economic loss [1]. There is general agreement that 
rheumatoid inflammation should be controlled as soon as possible, as completely as 
possible, and that control should be maintained for as long as possible, consistent with 
patient safety [2]. It is recommended [3] that, in nearly all cases, patients should be 
treated with a DMARD or "biologic” agent. DMARDs should be used in high doses, 
capable to reduce inflammation, unless full treatment effect is gained at lower dosage or 
limiting toxicity is reached. Treatment failure then follows a simple definition: "treatment 
failure exists when rheumatoid inflammation is not controlled” [3]. When adequate control 
is not achieved, the DMARD should be changed or another DMARD or "biologic” agent 
added [3]. Unfortunately, most patients achieve only partial suppression of rheumatoid 
inflammation and many lose therapeutic benefit after an initial good response. Additive 
combination therapy may also produce only temporary benefit [2]. In general, we cannot 
predict with enough certainty the disease course and occurrence of response and toxicity 
for individual RA patients. While enriched by new treatment options, the management of 
RA continues to be a challenge [2,4].
Accepting that the goal of treatment is to reach optimal control of rheumatoid 
inflammation or even remission, it is clear that management of RA should include 
systematic and regular evaluation of rheumatoid inflammation. Treatment efficacy should 
be monitored with the same seriousness as the monitoring of toxicity [5-7]. The treatment 
program can be accommodated if necessary, from both perspectives of benefit and harm 
[1]. Such a trade-off could be a good moment to include patient preferences and to 
educate the patient about treatment options. In daily clinical practice, regular and 
systematic monitoring of inflammatory activity is useful to:
- Understand if the therapy chosen is needed and effective.
- Assure that rheumatoid inflammation is still under control.
- Make sure that no over treatment is performed.
- Identify rapidly advancing disease with high levels of inflammatory activity over 
time and fast radiographic progression, where "aggressive” treatment may be 
needed [3].
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- Support the choice of specific DMARDs. It is advised to take the most effective 
DMARD first, but there is no simple rule as to the order of treatments [3].
- Adjust DMARD dosage in the titration of disease activity.
- Support treatment expectations. In some instances, a full response may take 
longer than expected, and it may be appropriate to continue the therapy if an 
adequate response may be achieved by additional treatment time [3].
An example of monitoring for the titration of inflammatory activity is depicted in the graph. 
The usefulness and feasibility of dose titration in RA patients treated with anti-TNFa is 
shown in a study presented by Den Broeder et al. [8] in this issue of Rheumatology, 
demonstrating the advantages of tailoring anti-TNFa treatment compared to the "one size 
fits all” dosing scheme. Initiatives to establish computerised decision support systems for 
the monitoring of RA have emerged in Switzerland and Sweden [4,9,10]. Generally, 
monitoring and documentation is not used regularly in daily clinical practice [11-13]. The 
statement by Pincus may be recognised: 'Many, if not most, clinicians feel it is not 
necessary to document obvious clinical improvement recognised by both the patient and 
the clinician. A positive response to the question "How are you doing?” is sufficient' [14]. 
In daily clinical practice, there are several barriers to regular monitoring that may not be 
different from the barriers for the use of outcome measures. Examples are: the 
apprehension of non-laboratory data as "soft”, unfamiliarity with scores and difficulty with 
their interpretation, uncertainty about the impact on clinical care or health, the resource 
of time and personnel, and fear to annoy patients with measurements [15-18]. It is 
important to recognise these barriers, but they are managable. By far the most important 
barrier is: how does a clinician know when rheumatoid inflammation is optimally 
controlled or in remission? which measures should be used? what are the criteria to state 
that inflammatory activity is under control?
There is general agreement regarding the measures and examinations that are most 
appropriate to evaluate change in randomised controlled trials evaluating DMARDs [19­
22]. In daily clinical practice however, the aim is to determine and evaluate actual status, 
rather than a change in status [19, 23]. There are no defined gold standards of severity 
for the measures used for assessment of RA. Thus, it is not clear "how low you have to 
go” in which measures, to be quite confident that there is remission or that inflammatory 
activity is under control. However, the measures that clinicians would apply in daily 
clinical practice preferably include the American College of Rheumatology (ACR) core
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set measures, for practical and methodological reasons. Even if those measures are 
approximating rather than measuring the underlying synovitis. The two approaches most 
established to measure change in randomised controlled trials (RCTs) are the ACR 
improvement criteria and the EULAR response criteria [21,22].
The ACR improvement criteria (e.g. ACR20) determine a patient a responder if there is 
improvement (e.g. >20%) in both tender and swollen joint counts, and in 3 of the 
following 5 measures: pain, patient global assessment, physician global assessment, 
disability, and an acute phase reactant [21]. The ACR improvement criteria are designed 
to discriminate placebo from verum in RCTs, they are not helpful in assessing actual 
status in clinic patients [19]. The main disadvantage of such a response measure is that 
the amount of inflammatory activity you end up with is unknown. To give further insight 
into status and prognosis, percentile methods for core set measures have been 
developed, with which severity status of an individual patient can be compared with a 
reference group [19]. However, it is a disadvantage when changes in multiple measures 
must be interpreted at the same time, while it is still difficult to interpret their meaning.
The EULAR response criteria determine the patient a good, moderate or non-responder, 
dependent on both the magnitude of improvement and the absolute level of the DAS28 
reached [22]. The DAS28 is an index that includes the results of swollen joint count, 
tender joint count, ESR and a general health question. The DAS28 ranges virtually from 
0-10, a score below 3.2 is defined as "low disease activity” . A low level of DAS28 over 
time reduces the probability of progression of radiological visible joint damage [24,25]. 
Thus, the DAS28 is suited to aid in determining and evaluating actual status and change 
in status, particularly when applied to individual patients with RA. As an example, the 
DAS28 was used to individually increase the dose of methotrexate (MTX), starting with
7.5 mg/week, in a trial on the effects of the addition of folates [26]. How the DAS28 can 
be used in a step-down regimen is demonstrated by the study of Den Broeder et al. [8]. 
Clinical variables, as in the DAS28, are just approximates of the underlying synovitis. 
Clinical assessments may be complemented by information from patient questionnaires 
such as the Rheumatoid Arthritis Disease Activity Index (RADAI) [27]. However, it is not 
possible to rely solely on questionnaire results to base treatment decisions on [28]. To be 
surer about the long-term course of RA in an individual patient, monitoring can include 
disability and joint damage.
It is important to monitor inflammatory activity on a regular basis, perhaps every visit, 
every 3 months, or with every change in DMARD and dose. In any case, inflammatory
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activity must not only be documented if the patient presents with clearly active 
inflammation, but also when improvement occurs or treatment effects are expected. 
Monitoring of long-term effects (disability and joint damage) may take place every 6 
months or annually. An important facilitation for clinical use would be, if the information 
needed to judge inflammatory activity is at hand shortly after the assessment. Then, 
relevant decisions can be made in presence of the patient.
In primary care, several RCTs are performed on the effectiveness of computerised 
decision support systems (CDSS) including measurement-feedback and guidelines, 
mainly in patients having hypertension, diabetes, or anticoagulation need, but also in 
patients with arthritis [29-37]. According to these studies, CDSS were generally 
ineffective in changing physician performance or health outcomes. It is important to 
realise that monitoring of RA is not an intervention that causes health effects, but 
medication may. Physician performance is the important link between monitoring and 
health effects through medication.
Conclusion
The goal of treatment of RA is to control rheumatoid inflammation as soon as possible 
and as completely as possible, and this control should be maintained for as long as 
possible. To evaluate if treatment goals are reached and to support accommodations of 
the treatment program, the management of RA patients in daily clinical practice should 
include systematic and regular evaluation of rheumatoid inflammation. For determining 
status and change of individual RA patients in daily clinical practice, core set measures 
and response criteria may be used with some care.
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Graph An example of the monitoring of disease activity (DAS, RADAI), disability 
(HAQ) and joint damage (X-ray) over time, in an individual RA patient.
^  DAS □ RADAI o HAQ ^  H-ray(W10)
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Objective Clinical Quality Management (CQM) in Rheumatoid Arthritis (RA) aims at 
reduction of inflammatory activity and pain in the short-term, and damage, and 
consequently disability, in the long-term.
Methods Within CQM as used in Switzerland rheumatologists are provided with a 
measurement feedback system with which they can regularly follow their patients. 
Inflammatory activity is measured with the Disease Activity Score (DAS28) and the 
Rheumatoid Arthritis Disease Activity Index Questionnaire (RADAI), damage with an X- 
ray score, disability with the Stanford Health Assessment Questionnaire (HAQ). 
Feedback is used to optimise therapy, which in the short term allows the activity of the 
inflammatory process to be adjusted or "titrated". In the long term, the therapy result for 
the individual patient is monitored by the course of disability and damage.
Results In this paper we present a series of cases to illustrate the usefulness of the 
CQM system in the management of individual RA patients.
Conclusion CQM in RA may be helpful when making decisions about adjustment of 
treatment, and to document and communicate these decisions based on quantitative 
data.
Introduction
Quality management focusing on improving health-outcomes may be defined as Clinical 
Quality Management (CQM) [1]. While effectiveness research examines "what works in 
medicine", CQM is applying this knowledge to improve care. It aims at a permanent 
improvement or optimisation of health-outcomes by modifying the process of care in an 
ongoing learning process [1].
The basis for CQM is the construction of a measurement-improvement system using 
standardised assessments to be applied in a predefined way. However, there are 
obstacles to be overcome if CQM methods should become common practice [1]. 
Practical obstacles, apart from the availability, are: time cost, unfamiliarity with 
standardised assessments and the meaningful interpretation of measures [2]. The 
measurement-improvement system should be useful for both clinicians and their 
patients. Thus, a key issue for successful implementation is that clinicians and patients 
experience an advantage from measuring standardised clinical and patient-oriented 
parameters. Most beneficial to the clinician is to have the data at hand when deciding 
about the therapy of individual patients, and therefore to make immediate use of such 
data.
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The fundamental problem in patients with Rheumatoid Arthritis (RA) is systemic 
inflammation. The assumptions of the current therapeutic approach are: 1) control of 
systemic inflammation reduces disease impact to the patient in the short-term, and 2) 
control of inflammation reduces damage, and consequent disability, in the long-term 
[3,4,5]. However, now there is increasing evidence that destruction of the joints can 
progress even in the absence of inflammation. Therefore, efficient control of inflammation 
may not prevent joint destruction completely [6].
As inflammation is suppressed with potentially toxic drugs, it is critical to find the optimal 
efficacious dose without introducing intolerable side effects. Especially if a disease- 
modifying antirheumatic drug (DMARD) has to be stopped and another drug has to be 
installed, precious time in which the inflammation is not sufficiently suppressed may be 
lost [7]. Therefore, the expected beneficial effects to the patient have to be monitored 
with the same conscientiousness as the surveillance for side effects. Nowadays in 
rheumatology there are measures available for disease impact, damage and disability, 
and there are response criteria, of which the methodological properties are known [8]. 
While these measures are now essential when conducting clinical trials [9], they may 
also be used in daily practice. Using these measures to optimise management in clinical 
practice leads to a decision on treatment that can be supported by quantitative data, 
rather than on "personal experience" and overall impression alone.
As a consequence, the activity of the inflammatory process, the primary target of medical 
therapy, can be adjusted or "titrated", similarly to blood glucose in diabetics or blood 
pressure in hypertensives.
In this paper we present a series of cases to illustrate the use, and to point out to 
potential caveats, of a practical CQM system in RA that was introduced to Switzerland in 
1997. The CQM allows not only for single patient feedback, but also for provider 
feedback and health service research.
Methods
Measures
The CQM in RA aims at reduction of inflammatory activity and pain in the short-term and 
the reduction of damage, and consequent disability, in the long-term. Within this 
framework, inflammatory activity and damage are intermediate clinical outcomes, while 
pain and disability are primarily patient-oriented outcomes (see Table 1).
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Inflammatory activity was measured with the Disease Activity Score (DAS28) [10,11]. 
The DAS28 is calculated from the results of a 28 swollen joint count, a 28 tender joint 
count and ESR (Westergren). The response to treatment can be valued according to the 
EULAR response criteria, and is dependant on the current level of DAS28 and the 
magnitude of change [11,12].
Damage was measured with X-rays of the hands and feet, that were scored according to 
a new method proposed by Rau, the so-called "Ratingen Score", which concentrates on 
damage to the joint surface [12]. The score was expressed as a percentage from the 
maximal possible score.
Pain was measured with the self-administered Rheumatoid Arthritis Disease Activity 
Index (RADAI) questionnaire, which also includes stiffness and global assessment of 
disease activity [13]. Disability was assessed with the modified Stanford Health 
Assessment Questionnaire (HAQ) [14,15].
Physicians are provided with manuals about the use of these scores, including 
information about their validity, reliability, sensitivity to change, and minimal clinical 
important differences. An extraction of this information is given in Table 2.
Data collection
The physician is provided with a single page record sheet showing two mannequins to 
mark swollen and tender joints, and space to fill in the ESR and medication information, 
while patients are provided with questionnaires. The sheets are sent together with the X- 
ray files to the co-ordination centre. The data are fed into a computer and a feedback 
report is produced, including graphical displays and tables, which is sent back to the 
physician. A full example of a feedback report is given in Graph 1, in Graphs 2-4 only the 
graphical part of the feedback report is presented.
The visits of the patient may be regularly scheduled or be at the initiative of the patient. 
The measures representing inflammatory activity and pain are measured every visit. 
Damage and disability are assessed once a year, in a fixed appointment.
Cases
The cases were selected out of the Swiss CQM database to show the use and caveats 
of the CQM tool. All cases are out-patients, attending on self-admission and have an 




In Case 1, it is illustrated how periods of increased inflammatory activity (flares) are 
presented in graphs and figures, and how the principle of titration of inflammatory activity 
works in practice.
This 65 year old woman, with a 14 year history of mild RA, treated initially with 
chloroquine and since 1995 with methotrexate, was followed using standardised 
assessment since November 1995 (Graph 1).
In 1995, when she volunteered in a trial comparing methotrexate to collagen [17], she 
developed a flare. With re-installation of methotrexate, disease activity decreased 
(February 1996). But only with the increase to 10 mg methotrexate (November 1996) 
was disease activity, as measured with the DAS28 (=1.9) and the RADAI (=0.3), 
adequately controlled. When methotrexate was stopped in July 1997, one week prior to 
foot surgery and not re-installed for 6 weeks, the patient had a flare again, with both a 
high RADAI (=4.9) and DAS (=6.3). With re-installation of methotrexate, disease activity 
could be titrated at the target of DAS28 (=3.2).
This case illustrates that with DMARD therapy, systemic inflammation can be virtually 
titrated within several weeks, similar to the titration of blood glucose in a diabetic within 
hours. It shows that a remission may be best understood as an often temporary state, at 
the lower end of the continuum of disease activity, which needs to be aimed at 
continuously through a consequent monitoring and adjustment of treatment. In our case 
remission with a DAS28 of <2.0 could be achieved once, and a low disease activity with 
a DAS28 <3.2 was achieved at four time points [10,11]. Cumulated disease activity did 
not result in damage or disability, as measured with X-rays and the HAQ. Joint 
destruction is unlikely if the disease activity is low over time [18,19,20].
Keeping patients on continuous adequate treatment is a challenge to the rheumatologist
[21]. The graphical display of the clinical status and disease scores is a language that 
patients can understand and may help to improve compliance. In communication, the 
use of quantitative data may finally convince our surgical colleagues of the importance to 
stop DMARDs for just a short period of time with major surgery, or to avoid stopping 
DMARD treatment at all with minor surgery [22,23].
Case History 2
This case illustrates that while in mild to moderate RA titration of disease activity towards 
a DAS28 below 3.2 or 2.0 [10] may be achieved using a single DMARD, patients with
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more severe RA may require more aggressive treatment, for instance combination 
therapy.
The 61 year old female patient suffers from RA since 13 years and has been treated with 
virtually all currently available DMARDs, including parenteral gold, D-penicillamin, 
methotrexate, sulfasalazine and cyclosporine. Despite these treatments damage 
progressed, requiring several orthopaedic interventions and leading to a considerable 
disability, with a HAQ score of 2.3.
With the use of standardised assessments starting in April 1996, it soon became evident 
that with her current methotrexate therapy alone, in a dose acceptable to the patient 
(unbearable nausea above the dosage of 17.5mg weekly), disease activity could not be 
titrated below 3.2 or even 2.0 over a longer period of time (Graph 2). There was an 
increase in radiological damage from April 1996 to October 1997. An attempted 
combination therapy with salazopyrine in an increasing dosage over the period of half a 
year from February to October 1997 was considered not successful. Only the 
combination with low-dose cyclosporine resulted in an acceptable control of systemic 
inflammation (DAS28=2.4).
It is illustrated that when faced with figures telling us about a poor prognosis, with an 
unacceptably ongoing high disease activity and damage, the physician is challenged to 
consequently and systematically try more aggressive treatment options [24,25]. Trying to 
attempt acceptable levels of disease activity may be worth while, even in patients with 
long standing RA and a long history of insufficient treatment.
In terms of measurement this case shows the often congruent course of the semi­
objective DAS and the subjective RADAI. In some instances, such as the flare in autumn 
1997, the DAS28 but not the RADAI pointed initially to the flare. Having information from 
both sources at hand may help to clarify in an unclear case, or to ascertain in the case of 
a congruent course of the indices.
Case History 3
This case, as well as the next case, illustrate some regularly encountered situations 
requiring individualised interpretation of measures, reminding us that treatment of RA is 
still an art rather than a cookbook approach.
The 58 year old woman suffers from RA since 7 years. She was first treated with 
parenteral gold, which had to be stopped because of the development of an allergic rash, 
then with chloroquine, which was stopped because of inefficacy, and finally, since 1993, 
with methotrexate.
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She was first seen in our clinic in January 1996 when she developed a flare after the 
cessation of methotrexate treatment. With reinstallation of methotrexate, the initially high 
DAS28 of 7.3 (Graph 3) receded to just 5.8, which is a response in terms of change 
(greater than 1.2), but not in terms of the level to be achieved, which should be lower 
than 3.2 (low disease activity), or even < 2.0 (remission) [10].
As can be seen from Graph 5, where the DAS28 and its components are shown, the 
number of swollen joints and the ESR decreased, but in the meantime the number of 
tender joints stayed at a very high level.
A second look at the Graph 3 reveals an extremely high RADAI with values up to 10, as 
well as a very high HAQ score of 2.4, whereas the X-ray score showed no joint 
destruction. Remarkably, the HAQ did not change with the values for swollen joints and 
sedimentation rate.
Indeed this patient did not only suffer from RA, but also from fibromyalgia with a low pain 
threshold. The discrepancy between the high HAQ as compared to the X-ray score, 
which was normal, is consistent with a previous report [26]. Patients with fibromyalgia 
had a higher perceived physical functional disability that was not explained by damage 
measures. It is also important to note that the DAS includes the number of tender joints, 
and in this case not only reflects systemic inflammation, but is also driven by a low pain 
threshold.
It is clear that using standardised assessment and indices requires a cautious look and 
individualised interpretation [27]. In this patient, disease activity needs to be adjusted 
based on sedimentation rate and the number of swollen joints, rather than the number of 
tender joints of the DAS.
Case History 4
In this case we will show that there are situations where one may chose to follow a 
patient using the course of swollen joints in combination with tender joints and pain.
This 51 year old female patient suffers from RA since 13 years and was successfully 
treated from 1987 to 1996 with d-penicillamine, and since April 1996 with methotrexate. 
As the treatment with methotrexate alone did not result in prolonged reduction of disease 
activity, combination therapy was started.
Firstly with hydroxychloroquine, which was insufficient to control disease activity (flare at
11.1996, see Graph 4). Therefore a triple therapy [25], with additional sulfasalzine was 
installed in 1997, which induced remission.
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It is remarkable in this case that there was no elevation of the sedimentation rate (ESR) 
above 15 in the 3 flares, but the values for ESR seem to deviate similarly as the DAS, 
RADAI and pain do. In other words, the ESR remained within the normal range, which 
may have led to an underestimation of true disease activity by the DAS28 in this patient. 
A low ESR in active RA could be found in some patients [28].
In Graph 6 there is a congruency seen between swollen joint count and tender joint 
count, the same congruency is seen in Graph 4 with pain and the DAS28. As in the 
previous case, the possibility of having an overall picture including information from both 
the physician and from the patient perspective allows for an ongoing adequate titration of 
disease activity.
This case illustrates that there is a need to be cautious when using indices such as the 
DAS28 for individual patients. Most measures are developed based on more or less 
homogeneous groups of patients. A measure is most likely to be valid for an individual, if 
that patient represents sufficient characteristics of such a group. But still, for individuals, 
the disease course and the suitability of a measure to reflect it are difficult to predict.
Discussion
Our cases illustrate the use of a set of standardised assessments within a measurement- 
improvement system to optimise treatment. As demonstrated, CQM may be helpful when 
making decisions on the adjustment of treatment, and to document and communicate 
these decisions based on quantitative data. The tables and graphs used in the feedback 
report allow the physician a quick overview of status and the course of the disease. The 
graphs are generally easily understood by the patient, which may enhance compliance 
with treatment. Positive experiences with the use of the CQM system have been made in 
Switzerland since 1997. With the participation of all university and large hospital 
rheumatology units and an increasing number of private rheumatology practices, the 
CQM concept has gained acceptance.
However, the use of CQM is not trivial and there are some burdens to overcome [2,29]. A 
problem of standardised assessment for daily practice is the time cost. With the inclusion 
of patient questionnaires, the effort made is shared by physician and patient [30]. It is 
important to limit the time costs for the physician to an acceptable level. In our 
experience, the time costs by the clinical assessments for the physician is regained by 
the time saved with the availability of useful data. But, the meaningful interpretation of 
such data requires familiarity with scores, which has to be achieved by regular practice 
[30]. In addition, reference data from clinical studies may help to interpret clinical status,
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or the disease course of a patient. However, the use of such data in clinical practice has 
not had wide attention. The measures used in the CQM are primarily developed for use 
in groups, not for individuals. The validity in application for individuals is enhanced by the 
inclusion of several measures and the inclusion of both clinical and patient-oriented 
outcomes.
In addition to the demonstrated use of the CQM to adjust drug treatment in individual 
patients, the cumulated data can be used for provider feedback and group analysis. 
Rheumatologists are free to use measures at self-defined time-points to adjust treatment, 
however, they are asked to repeat a complete assessment yearly, including X-rays. The 
yearly visits serve cohort analysis. The CQM thus allows for the identification of problem 
areas in treatment, for instance where a high degree of variation in treatment is seen. 
This may help professional societies to focus on the development of practice guidelines 
where most benefit can be expected. With a CQM program the implementation of 
practice guidelines can be monitored. It can be studied whether practice patterns 
change, and whether, and for whom, this results in hypothesised gains in health- 
outcomes.
CQM in RA is not a kind of ‘cookbook’, but a complementary tool to support decision 
making by the experienced rheumatologist, thus participation has been restricted to 
rheumatologists only. From a political perspective the concept may thus contribute to 
further establish the central role of the rheumatologist in the management of RA patients 
[32,33]. Last but not least, it seems critical that CQM stays within the medical community 
(here the rheumatology societies) and that the data are confidential. It may be successful 
only if CQM is not imposed from the top down and if physicians may be sure that their 
practice will not be scrutinised by third parties. Otherwise it is likely to produce fear, 
behaviour to protect one's own position, and discrediting of information and its source.
In conclusion, CQM is a potentially useful tool for continuous improvement of patient 
care. The successful integration into clinical practice is the cornerstone for long-term 
implementation of CQM. It needs to be studied whether the use of CQM results in 
improved health outcomes in the short and long term, for patients with RA.
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Table 1 Measurements used in the Swiss Clinical Quality Management in 
Rheumatoid Arthritis.
PHYSICIAN PATIENT (Self-assessment)
Inflammatory Activity DAS28 RADAI
- Swollen Joint Count
- Tender Joint Count
- ESR
- Pain
- Painful Joint Count
- Global Assessment
- Morning stiffness
Damage and Disability X-ray Score HAQ
Table 2 Practical use and interpretation of measurements useful in the titration 
of disease activity in RA.
Measurement DAS28 Rx/10 RADAI HAQ
Practicability
Time for Physician 5 min. 3 min.
Time for Patient +/- 3 min. +/- 5 min.
Administration* Short Term Long Term Short Term Long Term
Interpretation
Variable Type Continuous Continuous Ordinal Ordinal
Range1 0 - 10 0% -100% 0 -  10 0 - 3
Reference Values1 4.1 (1.5) -- 3.0 (1.6, 4.8) 1.0 (0.4, 1.8)
Minimal Clinically Relevant Difference# 0.6 3.3% -- 0.17
Target < II 2 No Progression 0 0
* Short term: weeks to months; Long term: 12 months
T For all scores: lower scores represent a better health status. For Rx/10, RADAI and HAQ, 0 reflects a normal 
value. Please note that the lowest border of DAS28 is 0.16, values higher than 9 are seldom seen in practice. 
1 Mean (sd) or median (25, 75 percentile) in our Swiss CQM population.
# References for minimal clinically relevant differences are: [11,13,34].
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Physician : Dr. TL
Patient : 1
Date of last visit : 08.98
Feedback Report SCQM
O HA O RADA Pai O X-ray/10 O DA O ESR/1
10
9
11.95 3.96 6.96 9.96 12.96 3.97 6.97 9.97 12.97 3.98 6.98 8.98
Measure: 11.95 12.95 02.96 08.96 11.96 04.97 08.97 10.97 06.98 08.98
RADA 0.5 6.4 0.6 1.4 1.3 0.3 4.9 3.3 2.6 1.4
Pai 0 8 0 0 0 0 7 1 3 1
DA 3.6 4 3 4 4 1.9 6.3 3.2 3.8 2.8
HA 0.9 0.3 0 0.8 0 0.9 0.5 0.4
X-ray 0 0
Blood-test: 11.95 12.95 02.96 08.96 11.96 04.97 08.97 10.97 06.98 08.98
ESR (mm/h) 2 2 1 3 3 1 4 1 1 1
Leuco (1000/ul) 3.6 5.24 4 3.6 3.8 3.9 4.5 4.2
Creatinin (umol/l) 8 9 9 10 10 10 9 10
Hb (g/dl) 12. 1 11.8 12. 12. 12.4 12.5 11.
Thrombo (1000/ul) 14 18 16 16 21 21 16 16
GPT(ALT) (umol/l) 3 2 1 1 1 1 9 3
Medication 11.95 12.95 02.96 08.96 11.96 04.97 08.97 10.97 06.98 08.98
Collage 1
Aulin 10 10 5 20 5 10 10 10
Methotrexate i.m. 7.5 7.5 7.5 1
Methotrexate p.o. 1 15 1 17. 17.
* 6 weeks of withdrawel of MTX, reinstallation on 08.97
Graph 1. Physician’s feedback report of case 1.
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o  HAQ o  RADAI •  Pain o  X-ray/10 o  DAS o  ESR/10
Graph 3. Graph from the physician’s feedback report of case 3.
4.96 8.96 12.96 4.97 8.97 11.97
Graph 4. Graph from the physician’s feedback report of case 4.
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Physician : Dr. TL
Patient : 3
Date of last Visit : 8.98
O swollen joints O tender joints O ESR/1 K disease activity score
DAS28
Graph 5. Graphical representation of the disease activity score 
(DAS28) and its components for case 3.
DAS28 Physician : Dr. TL
Patient : 4
Date of last Visit : 11.97
O swollen joints O tender joints O ESR/1 —* — disease activity score
Graph 6. Graphical representation of the disease activity score 
(Da S28) and its components for case 4.
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Chapter 4
Feasibility and validity of the RADAI, a self-administered Rheumatoid
Arthritis Disease Activity Index.
1 1 1 'yJaap Fransen', Thomas Langenegger', Beat Michel' and Gerold Stucki2 
for the members of the Swiss Clinical Quality Management in Rheumatoid Arthritis
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Objective The goal of the Rheumatoid Arthritis Disease Activity Index (RADAI) is to 
provide an easy to use assessment of disease activity. It is a self-administered 
questionnaire that combines five items into a single index: current and past global 
disease activity, pain, morning stiffness and a joint count.
Methods A sample of 584 rheumatoid arthritis (RA) patients was used to assess the 
internal consistency and the convergent validity of the RADAI.
Results Cronbach's alpha was 0.87, supporting the summation of the items into a single 
index. The index correlates best with physicians' global assessment (r=0.59; p<0.0001), 
HAQ (r=0.55; p<0.0001) and number of tender joints (r=0.55; p<0.0001). Correlation with 
ESR is low (r=0.27; p<0.0001). The RADAI and DAS28 are correlated (r=0.53; 
p<0.0001), but there is low agreement.
Conclusion The RADAI is valid to assess disease activity in RA patients. However, the 
RADAI may not automatically replace other measures of disease activity, such as the 
DAS28.
Introduction
The evaluation of the disease course of rheumatoid arthritis (RA) requires 
comprehensive assessment of process and outcome. As there is no gold standard of 
disease activity of RA, there are still multiple measures used and needed to assess 
different aspects of the underlying disease.
For clinical trials in RA there is agreement on which aspects of disease activity have to 
be assessed at a minimum [1]. According to specific study objectives, measures may be 
added. This minimal core set contains: an acute phase reactant, a pain rating, a patient's 
global assessment of disease activity and a physician's global assessment of disease 
activity, a swollen and a tender joint count, a measure for disability and, for studies 
lasting longer than one year, a measure for joint damage to the hands and feet [1].
Three measures of the core set, that is, number of swollen joints, number of tender joints 
and erythrocyte sedimentation rate (ESR), have been integrated in a single index of 
disease activity, the disease activity score (DAS) [2,3].
Similarly, the items pain and patient global assessment of disease activity are used in a 
questionnaire format on disease activity, together with other items that are not in the 
core set such as duration of morning stiffness [4-7]. Whereas joint counts and ESR 
depend more or less on the physician's judgement, pain and patient global assessment 
reflect patient perceptions.
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The Rheumatoid Arthritis Disease Activity Index (RADAI) [6], is a modification of the 
questionnaire introduced by Mason [4]. The goal of the RADAI is to provide an easy to 
use assessment of RA disease activity, which serves as a complement to the physician’s 
assessments and by which the physician's assessment in certain situations could be 
omitted [6], especially in observational studies or within patient management, where 
laboratory measurements and clinical assessments may not be possible, or may be too 
demanding.
The single index approach of the RADAI was found to be valid based on its high 
association with clinically assessed joint synovitis and the acute-phase response, the 
high internal consistency, and the loading of the items on a single factor [6]. However, 
the sample of RA patients was relatively small (N=55).
The objective of the current study is to assess the internal consistency and the 
convergent validity of the RADAI total score, as well as the feasibility of the 
questionnaire, cross-sectionally in a larger and broader population than that in which the 
RADAI was originally tested.
Patients and methods
Patients
We made use of the data from a running cohort of RA patients involved in a clinical 
quality management project, Swiss Clinical Quality Management in RA (SCQM) [8]. 
Participating rheumatologists in SCQM come from the university and regional hospitals 
and private practice. Participating rheumatologists are strongly advised to include all their 
RA patients, but are free to decide for themselves as to which patients they include. 
Patients may be included if they have a diagnosis of RA according to the 1987 revised 
ACR criteria [9] and give their written consent. Prerequisite is the ability to communicate 
in either French, German or Italian.
Data collection
The inclusion visit includes clinical examination and the taking of a blood sample. 
Questionnaires are filled in by the patient at home and sent back to the treating 
physician. The data are collected by the physician and sent to the co-ordination centre. 
The co-ordination centre provides the physician with a feedback report. The data are 
stored anonymously to serve for further feedback. Data are only accepted by the centre if 
all forms are present.
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Variables
The patient's personal data include gender, date of birth and, if available, the date of 
diagnosis of RA according to the patient record. The laboratory measures include 
rheumatoid factors (RF) (Waaler-Rose or Singer-Plotz) and Westergren erthrocyte 
sedimentation rate (ESR).
The clinical measures include a 28 swollen joint count, a 28 tender joint count [3] and a 
global assessment of disease activity by the physician, on an anchored 11 point 
numerical rating scale (11-NRS). The patient provides a pain rating (11-NRS) and a 
global assessment of disease activity (11-NRS). The Disease Activity Score (DAS28) 
was calculated from the results of the 28 swollen joint count, the 28 tender joint count 
and ESR [3,10]. The questionnaires filled in by the patient included the RADAI [6] and a 
German version of the Stanford Health Assessment Questionnaire (HAQ) [11,12].
Contents of the RADAI
The RADAI is a 5 item questionnaire. The items ask the patient about 1) global disease 
activity in the last 6 months, 2) disease activity in terms of current swollen and tender 
joints, 3) arthritis pain, 4) the duration of morning stiffness and 5) tender joints to be rated 
in a joint list. The joint list asks about pain in the left and right shoulders, elbows, wrists, 
fingers, hips, knees, ankles and toes. The first three items are all rated on an anchored 
numerical rating scale from 0 to 10, where higher scores indicate more disease activity. 
The scores on the last two items range from 0-6 and 0-48 respectively, but are 
transformed on the same scale of 0-10. If all items are answered, the scores are added 
and divided by the number of items to provide a single index of patient-assessed disease 
activity. (See table 2).
Data processing
The data are stored in an Access 7.0 relational database and have been processed with 
SAS 6.11 statistical software package.
Statistical analysis
For the description of differences in the population, the two sample T-test or two-sample 
Wilcoxon test were used for continuous data, the Chi-square test was used when 
comparing numbers of patients.
Feasibility was assessed descriptively by the number of missing RADAI scores and the 
number of missing items.
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Validity was assessed by a) the correlation of the single RADAI items with core set 
measures. Expected were moderate correlations and a low correlation for ESR. For all 
correlations, Spearman's correlation coefficient was used; b) the internal consistency 
using Cronbach’s alpha. An internal consistency of 0.80 is considered adequate on a 
group level [13]; c) the correlation of the RADAI total score with the scores on the core 
set measures. It was expected that the highest correlations were to be found with the 
(semi-objective) tender joint count and the (patient questionnaire) HAQ, and the lowest 
with ESR; d) the relation of the RADAI to the DAS28, by correlation and by analysing 
differences of RADAI scores between groups stratified by DAS28-levels [3], ranging from 
being in remission to high disease activity, with use of Kruskall-Wallis test. The 
correlation of RADAI with DAS28 was expected to be moderate, as the DAS28 includes 
ESR. Probability values lower than 0.05 (two-sided) were regarded as significant.
Results
Patients
After an inclusion period of 16 months, the data of 584 patients with an inclusion visit 
were entered in the database. Virtually all patients were out-patients. Forty-two percent 
of the patients consulted a rheumatologist at a university clinic, 30% at a regional 
hospital and 28% in a private practice. Most of the patients were female (72%). Female 
patients had a larger median disease duration and there are proportionally less women 
with early RA as men (see Table 1). Disease duration (time since diagnosis) of the total 
sample ranged from less than one year to 58 years. The HAQ scores were rather 
uniformly distributed from 0 to 3, median 1.1 (interquartile range 0.4 - 1.8) with a 
somewhat higher amount of 0 scores and a gradual falling off near the scale’s upper end. 
The mean score of the DAS28 indicates a moderate level of disease activity (see table 5) 
[3].
Data completeness
The data that were most incomplete were the date of diagnosis, with a 93% completion 
rate and the RF laboratory test, with a 96% completion rate.
RADAI scores
The distribution of RADAI scores was positively skewed and showed a slight floor effect 
(see Figure 1). Fourteen percent (n=81) of the patients had a score lower than 1, no 
patient had a maximal score. The floor effect means that patients with a low RADAI
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score may not be able to adequately express a possible improvement in the future [13]. 
In Table 2 the median scores per RADAI item are given. The scores on the first three 
items are, relatively to their possible range, higher than on the last two items. All items 
show similar distributions as in the total score.
Feasibility
A RADAI score was available in 97% of the 584 patients. Eight patients had all RADAI 
items missing. Another 12 patients had some items missing, for these cases the RADAI 
was not calculated. The single items had each a completion rate of 98%.
Validity
a) In Table 3, the correlations of the single RADAI items with measures of the core set 
are shown. The item on morning stiffness correlates least with all core set measures, all 
the other RADAI items correlate moderately.
The RADAI items had the least correlations with ESR and swollen joint count. The items 
on pain and patient global assessment, which are in both the RADAI and the core set, 
are highly correlated.
b) Cronbach's alpha for assessing internal consistency was 0.87 for the RADAI total 
score. In Table 4 it can be seen that the items "disease activity today” and "arthritis pain 
today” had the highest correlations with all other items, followed by "disease activity in 
the last six months" and the "tender joint list". The internal consistency, represented by a, 
is raised the most by leaving the "morning stiffness" item out.
c) The correlations of the RADAI total score with the scores of the core set measures are 
represented in Table 5. The mean DAS28 indicates a moderate level of disease activity 
[3]. The RADAI total score correlates best with the physician's global assessment, tender 
joint count and the HAQ. The correlation with ESR is low.
The DAS28 correlates well with the physician’s global assessment. Two of the DAS28 
elements, the swollen and the tender joint counts, correlate relatively well with 
physician's global assessment of disease activity themselves, r=0.65, p<0.0001 for both 
(not shown).
d) In Table 5 it is shown that the RADAI correlates moderately with the DAS28. In the 
scatter plot of Figure 2, a wide scatter with an impression of curvilinearity can be seen, 
the latter is primarily caused by the skewed distribution of the RADAI, whereas the 
DAS28 has a normal distribution [13]. The correlation of the HAQ with the DAS28, 
r=0.51; p<0.0001, was similar to that of the RADAI with the DAS28. The two
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questionnaires RADAI and HAQ correlated with r=0.56; p<0.0001. In Table 6 it is shown 
that the RADAI scores of the groups according to the DAS28 levels [3] of disease activity 
are significantly different (Kruskal-Wallis, p<0.0001).
Discussion
The goal of the RADAI is to provide an easy to use assessment of disease activity in RA 
patients, especially in observational studies or within patient management, where 
laboratory measurements and clinical assessments may not be possible or may be too 
demanding [6]. The results of this cross-sectional study show that the RADAI is feasible 
in its use by patients and can validly assess disease activity, in a broad sample of RA 
out-patients.
In terms of feasibility, a vast majority of patients can complete the questionnaire in 5-7 
minutes. In this study, the low rate of items that were left blank may indicate that the 
items were adequate for the patients. In addition, there was a low rate of questionnaires 
that were not filled in at all, so the acceptance seems to be good.
In terms of validity, the internal consistency of the RADAI is quite high for a questionnaire 
with only five items [13]. The correlations between the RADAI items and the internal 
consistency are supporting the summation of the item scores into a total score. The 
theoretical advantage of the combination of several items into a single index include the 
higher reliability and reduction of the chance of making a type I error [14]. A problem with 
an index is that it is less easy to interpret. The RADAI total score has been shown to be 
able to measure disease activity: it correlates moderately well with core set measures of 
disease activity where it is expected, and especially relevant, with the DAS28. Further, 
RADAI scores differ significantly between groups with different disease activity levels 
according to the DAS28.
With respect to the range of disease duration and the degree of disability based on HAQ 
scores, this study sample represents a broad selection of RA patients. One advantage of 
this sample is that it represents RA patients in "real life” circumstances.
The most important study limitation is that the selection of patients by the rheumatologist 
is not controlled or known, even if rheumatologists were encouraged to include all their 
RA patients. It is possible that this population represents more severe RA patients. One 
reason is that general practitioners are not directly involved in the Clinical Quality 
Management project, but they may see patients with mild RA relatively more often then 
rheumatologists do.
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Most studies on reliability and validity of patient's perception of signs and symptoms of 
RA are about joint counts. In several studies it has been shown that patient joint counts 
are reliable [15-17]. The same joint list as used in the RADAI was assessed for test- 
retest reliability by Stucki [6]. Kappa values ranging from 0.52-0.72 were found for the 
different joints. Despite adequate reliability within patients, there is no sufficient 
agreement between patients and clinicians on joint counts [15-17]. For almost the same 
joint list as used in the RADAI, Hanly [7] found an Intraclass Correlation Coefficient (ICC) 
of 0.31 for the number of tender joints and ICC of 0.35 for the tender joint score. For that 
same format, Mason [4] found ICC’s ranging from 0.52 to 0.88 for the several joints and 
an ICC of 0.81 for the total joint score.
The disagreement between patients and clinicians on the rating of joints may be caused 
by the tendency of patients to rate pain [7] and joint involvement [15-18] higher than 
clinicians generally do. The different perspective of patients and physicians is illustrated 
by the findings of Taal [17]: the patient (swollen and tender) joint count correlated with 
the patient’s pain rating, the physician (swollen and tender) joint count correlated with 
ESR, and both counts correlated with physical disability. Hewlett [18] used separate joint 
counts for the symptoms pain, heat, swelling and stiffness, and stated that patients 
clearly can discriminate between them. However, Hanly [7] found that patients cannot 
rate swelling validly, and no agreement between physician and patient could be found for 
swollen joint count and swollen joint score.
The reliability and validity of general ratings on pain, global disease activity and morning 
stiffness is less extensively studied. For the ratings that are identical to the RADAI items 
on disease activity today, pain and morning stiffness, there was a good test-retest 
reliability found by Hanly [7], with ICC’s ranging from 0.81 to 0.85. The difference with the 
RADAI format is that a Visual Analogue Scale (VAS) was used. For the Numerical Rating 
Scale (NRS) as used in the RADAI, Bosi Ferraz [19] found that RA patients can rate their 
amount of pain as reliably (r=0.96) as with a VAS (r=0.94).
In concordance with these findings, in the RADAI joint count, the patient is asked to rate 
pain per joint, but not to rate swelling separate from pain. Current pain, morning stiffness, 
and disease activity (in terms of swelling and tenderness) are separate items. Pain as a 
major symptom in RA is addressed by two items. The item on "disease activity in the last 
6 months” is held globally, and does not want to discriminate between different 
symptoms.
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The DAS28 and RADAI are reasonably well related (r=0.53), but this does not 
automatically mean that the DAS28 (with a swollen and a tender joint count and ESR) 
can be replaced by the RADAI.
The first reason is, looking at the wide scatter in the plot of RADAI and DAS28 (Figure 2), 
that it is not likely that there is sufficient agreement to predict RADAI scores out of DAS 
scores with a small enough confidence interval [20]. Differences in scaling and 
distribution are likely to prevent sufficient agreement between laboratory, clinical and 
patient measures in advance.
The second reason is that DAS and RADAI have different contents. The DAS is parallel 
to a clinical judgement and the RADAI is a reflection of patient's perception of signs and 
symptoms. It is in general unlikely that there is enough agreement between process 
estimators, for instance CRP or ESR, and outcome measures as signs and symptoms. 
Illustratively, one failed to develop a self-report articular index that correlated with plasma 
viscosity, the latter used as marker of inflammation [18]. Several studies report no or 
relatively low correlations of patient questionnaires with laboratory determinants of 
disease activity such as CRP or ESR [6,21-24].
However, in addition to laboratory and clinical assessments of disease activity, the rating 
of patient perception of signs and symptoms is useful to assess the burden of disease to 
the patient. Burden of disease in terms of disability can be assessed with instruments 
such as the HAQ [11] or AIMS-2 [25]. The RADAI is reflecting burden of disease in terms 
of impairments. In this study, the HAQ was related to RADAI as well as to the DAS28. 
Based on factor analysis, Mason [26] pointed out that a measure of signs and symptoms 
(RADAR) provides complementary information to disability (AIMS-2) rather than 
duplicative. Further, in patient management as well as in trials, concordance of patient 
perceptions with physicians' judgement will enhance trustworthiness of interpretations 
about the underlying disease process.
The major goal of the RADAI is the disease evaluation over time in patient management 
or in clinical studies. If the RADAI, as a measure of disease activity, is sufficient in 
comparison to the DAS28 in guiding the physician in the management of individual 
patients must be clarified in the future. For any longitudinal use, it is needed to assess 
the smallest detectable difference of the RADAI and its sensitivity to change. Also, 




The RADAI has shown to be feasible and valid in the assessment of disease activity in a 
large cross-sectional sample of RA patients. The RADAI as measure of patient perceived 
disease activity is related with, but may not automatically replace, other measures of 
disease activity such as the DAS28.
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Table 1 Population characteristics.
Males Females Total
N 1 64 420 584
Age, yrs mean (sd) 58 (12) 59 (13) 59 (12)
Disease Duration, yrs median (IQR) 5 (2-13) 8 (3-17) * 8 (3-15)
Disease Duration < 2 yrs, n 56 (34%) 90 (21%) * 146 (25%)
Rheumatoid Factors +, n 110 (67%) 295 (70%) 405 (69%)
*  p < 0.001, for gender differences; IQR = interquartile range.




1. In general, how active has your arthritis been over 0-10 4 (2-6) 
the past 6 months?
2. In terms of joint tenderness and swelling, how active 0-10 3 (1-6) 
is your arthritis today?
3. How much arthritis pain do you feel today? 0-10 3 (1-5)
4. Were your joints stiff when you woke up today? If 0-6 1 (0-2) 
yes, how long did this stiffness last? no=0; <30
minutes=1; 30 minutes-1 hour=2; 1-2 hours=3; 2-4 
hours=4; >4 hours=5; all day=6
5. Please indicate the amount of pain you are having 0-48 10 (4-18) 
today in each of the joint areas listed. none=0;
mild=1; moderate=2; severe=3 Shoulders, elbows, 
wrists, fingers, hips, knees, ankles, and toes
Total RADAI score 0-10 3.0 (1.6-4.8)
Score values denote median (interquartile range). For the calculation of the total score the 
items 4 and 5 are standardised on a scale of 0 to 10.
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1 (arthr. 6 months.) .23 .35 .45 .50 .67 .71 .46
2 (arthr. today) .22 .35 .47 .52 .81 -- .45
3 (pain today) .23 .33 .48 .53 -- .81 .51
4 (morning stiffness) .17 .25 .36 .36 .49 .47 .37
5 (joint list) .26 .32 .50 .45 .65 .65 .53
All correlations are significant at a level p<0.0001. 
Identical items are marked with -- .
Table 4 At the left: correlations between the RADAI items. At the right: 
correlations (r) of a RADAI item with all other items, Cronbach’s 
alpha (a) of all other items without the single RADAI item.
RADAI-item 2 3 4 5 r a
1 (arthritis. 6 months.) 0.70 0.65 0.37 0.51 .67 .85
2 (arthritis. today) 0.81 0.46 0.62 .81 .82
3 (pain today) 0.47 0.67 .81 .81
4 (morning stiffness) 0.48 .51 .89
5 (joint list) .69 .84
p<0.0001 for all values. Scores for r and a  are standardised to have unit variance.
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Table 5 Scores of several indictors of disease activity and correlations with 




ESR 20 (10-33) .27 --
Swollen joint count 0-28 4 (1-9) .39 --
Tender joint count 0-28 3 (1-8) .55 --
Pain rating 0-10 3 (1-5) -- .46
Patient global assessment 0-10 3 (1-6) -- .46
Physicians global assessment 0-10 2 (1-4) .59 .72
HAQ 0-3 1 (0.4-1.8) .56 .51
DAS28 0-10 4.3 (1.4) .53
Score values are median (interquartile range), except for DAS28 where mean (sd) is given.
Note that, as the swollen and tender joint count and ESR are used for calculating the DAS28, 
and pain rating and patient global assessment for calculating the RADAI, these correlation values 
were not calculated. All correlations are significant at p<0.0001.
Table 6 DAS28 groups are formed according to the 
degree of disease activity.




DAS28 < 2.0 42 1.3 (0.5) 1.0 (0.5-1.9)
2.0 < DAS28 <= 3.2 120 2.7 (0.3) 2.2 (1.0-3.6)
3.2 < DAS28 <= 5.1 260 4.2 (0.5) 2.9 (1.8-4.5)
DAS28 > 5.1 136 6.1 (0.7) 4.9 (3.5-6.5)
IQR=interquartile range.
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Figure 1 Scoring on the RADAI in this population is skewed and shows a slight 
floor effect.
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Figure 2 Plot of RADAI against DAS28.
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Each observation is marked with a °, observations that are covering each other are indicated by •.
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Chapter 5
Responsiveness of the self-assessed Rheumatoid Arthritis Disease 
Activity Index (RADAI) to a flare of disease activity.
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Abstract
Objective The objective of this study is to assess the responsiveness of the Rheumatoid 
Arthritis Disease Activity Index (RADAI) for increases in disease activity in rheumatoid 
arthritis (RA) patients, with the occurrence of a flare of disease activity as an external 
standard.
Methods Post-hoc analysis of data from a randomized double blind controlled trial of 
MTX versus Collagen II (N=92). Responsiveness is analyzed by the correlation of 
change in the RADAI with change in the Disease Activity Score (DAS28), and the ability 
of the RADAI to detect a flare by plotting a receiver operating characteristic (ROC) curve 
and standardized effect size (SES). The contribution of the single RADAI items to the 
total change is analyzed by absolute values, the standardized response mean (SRM), 
and correlation of item score change with the total RADAI score change.
Results The changes in the RADAI correlated highly (r=0.70, p<0.0001) with changes in 
the DAS28. The area under the ROC curve was 0.87 (95%CI: 0.78-0.95) for the RADAI, 
which was similar to the DAS28. The SES for the RADAI was 1.56, which was again 
similar to the DAS28. The RADAI items on "past global disease activity” and "morning 
stiffness” contributed the least to the total score change.
Conclusion This study provides evidence that the RADAI is sensitive to detect relevant 
increases in disease activity in patients with RA. The RADAI may complement clinical 
measures in clinical studies, or may be used as a proxy for disease activity in 
epidemiological studies.
Introduction
As there is no ‘gold standard’ of disease activity in rheumatoid arthritis (RA), multiple 
measures are used and needed in clinical studies [1], as well as for monitoring individual 
patients in clinical practice for disease management [2]. Progress has been made in 
rheumatology by the adoption of a ‘core set’ of measures to be used in the trials of 
antirheumatic drugs [3], and by the use of index measures [4]. With ‘core set’ and index 
measures, the comparability between studies is enhanced.
The main advantages of indices over single measures are the avoidance of duplicity and 
increased sensitivity to change [4]. The avoidance of duplicity reduces the risk of making 
a type I error when performing multiple statistical testing and omits the difficulties arising 
when trying to interpret different changes in multiple measures simultaneously. Increased 
sensitivity to change is a result of reduction in measurement error [5,6]. Combination of 
items to increase validity and reliability is common practice for questionnaires. The main
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disadvantages of indices are concerns over validity and practical problems such as 
interpretation and computational difficulties [4]. The validity of an index depends on the 
validity of the measures that are included and their appropriate weighting. Interpretation 
of an index becomes easier when more information from (e.g. discriminative or 
predictive) validity studies is available and when familiarity with an index is growing.
The Disease Activity Score (DAS), combines erythrocyte sedimentation rate (ESR), a 
swollen joint count, a tender joint count (and sometimes a general health assessment) 
into a single index [7]. An index that is self-administered is the Rheumatoid Arthritis 
Disease Activity Index (RADAI), a short questionnaire that combines five items into a 
single index: current and past global disease activity, pain, morning stiffness and a joint 
count. [8,9] The RADAI was developed to complement clinical measures in clinical 
studies and to serve as a proxy for disease activity in epidemiological studies [9].
While the RADAI has been shown to be a valid measure of disease activity cross- 
sectionally [9,10], its responsiveness has not been studied. However, a major objective 
of the RADAI is the measurement of change. Measures that are cross-sectionally valid 
are not necessarily responsive [11]. Responsiveness is the ability of a measure to 
capture clinically important changes [11-13].
Until now, most attention concerning responsiveness in RA is implicitly given to changes 
in direction of improvement, however, in a fluctuating chronic disease such as RA, 
patients show worsening as well [14]. A measure that showed adequate responsiveness 
in the direction of improvement, must not necessarily show the same responsiveness in 
the opposite direction. For constructed measurement instruments as the RADAI, this 
may depend on the scaling properties, i.e. unidimensionality of the scale [15], item 
spacing [16], and relative scale length (ceiling or floor effects) [17].
The objective of this study is to assess the responsiveness, or sensitivity to change, of 
the RADAI for increases in disease activity in patients with RA. As an external standard 
of change, the occurrence of a flare of disease activity was used. To assess concurrent 
validity, the RADAI is compared with the DAS28. In addition, to assess content validity, 





We made use of the data from a randomized placebo controlled trial of methotrexate 
(MTX) versus Collagen II, that examined whether Collagen II could sustain a MTX 
induced treatment effect. The study sample and design was described in detail by 
Hauselmann et al. [18). Informed consent was obtained from all patients before inclusion. 
Included were patients with a diagnosis of RA, according to the American College of 
Rheumatology (ACR) criteria of 1987 [19], and a functional status of class I-III [20]. The 
patients had to be on unchanged MTX monotherapy for at least 8 weeks. Existing 
additional medical treatment with glucocorticosteroids or NSAIDs was allowed, if the 
dose was unchanged for the last 2 weeks and the dose of glucocorticosteroids was 
<12.5 mg/day. Excluded were patients younger than 18 years, and patients who had had 
intra-articular glucocorticosteroid injections within 3 weeks before study begin.
Patients (N=92) were randomized to receive Collagen II with MTX placebo or MTX with 
Collagen II placebo for 3 months, in a blinded manner. If there was existing additional 
treatment with NSAIDs or glucocorticosteroids, the doses were kept constant for the 
entire trial period. The study protocol was approved by the ethical committee of the 
University Hospital Zurich.
Measurements
The patients were assessed by the same clinician, who was blinded for group 
assignment, at baseline (t=0), at 30 days (t=1) and at 90 days (t=2). At baseline, 
sociodemographic data were obtained, radiographs of hands and feet were made and 
scored according to the Larsen method [21,22]. Laboratory measures included tests for 
Rheumatic factors (RF), Anti Nuclear Antibodies (ANA), and Human Leucocyte Antigen 
(HLA) class II typing [23,24], with subsequent classification according to RA association 
[25]. The following measures were obtained at all visits: Westergren erythrocyte 
sedimentation rate (ESR) and levels of C-reactive protein (CRP), number of swollen 
joints (28 joint count), number of tender joints (28 joint count), physician global 
assessment of disease activity (11-Numerical Rating Scale), pain assessed by the 
patient (11-NRS), and patient global assessment of disease activity (11-NRS).
The DAS28 (DAS28 S+T) was calculated from the results of the joint counts and the 
ESR [26]. A German version of the Stanford Health Assessment Questionnaire (HAQ) 
[27,28] and a German version of the RADAI [9] were used.
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The RADAI is a 5 item questionnaire. The items ask the patient about 1) global disease 
activity during the last 6 months, 2) disease activity in terms of swollen and tender joints 
today, 3) arthritis pain today, 4) the duration of morning stiffness, and 5) tender joints to 
be rated in a joint list (see Table 3). The first 3 items are all rated on an anchored 
numerical rating scale from 0 to 10, where higher scores indicate more disease activity. 
The scores on the last two items range from 0-6 and 0-48 respectively, but are 
transformed onto the same scale of 0-10. Demand is that all items are answered. The 
scores are then added and divided by the number of items to provide a single index of 
patient assessed disease activity.
The ability of the patient to follow the study protocol was recorded either as regular 
termination or as discontinuation, with subsequent registration of exact study duration 
and the specific reason for dropping out. Dropping out was immediately followed by the 
clinical and laboratory assessments as described before.
A drop-out due to a flare of disease activity was defined as a patient perceived increase 
in disease activity, leading to a wish to quit the study protocol, and/or a need for a 
change in medication that caused a protocol violation.
Statistical analysis
Patients who discontinued the study were analyzed for drop-out reasons. Patients with 
reasons for discontinuation other than a flare of disease activity (e.g. adverse effects), 
were excluded. Thus, two groups of patients could be formed: patients who discontinued 
(flare group), and patients who stayed in the study (non-flare group). The groups were 
formed without classification according to study medication, because splitting up the 
study sample into four groups would induce a significant power loss. To our knowledge, 
no differential effects between MTX and Collagen II can be expected in the case of a 
flare on the clinical parameters that are most relevant for this study, i.e. ESR, number of 
swollen and tender joints, and patient perception of disease activity. For data with a 
distribution that was approximately normal (according to the histogram, normal 
probability plot, median and mean, skewness and kurtosis) parametric statistics were 
applied and means and standard deviations are presented. For data with a skewed 
distribution, non-parametric statistics were applied and medians and interquartile ranges 
are presented.
The flare group and the non-flare group were analyzed for comparability at baseline. 
Between-group analysis was performed with the Chi-square test or Fisher Exact test, the 
two sample t-test, or the two sample Wilcoxon test, where appropriate.
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The changes between baseline of the RADAI, the DAS28 and the other indicators of 
disease activity, and the moment of study termination, were compared between both 
groups. For analyzing within-group differences the one-sample t-test was used, for 
between-group differences the two-sample t-test as well as the Wilcoxon test were used. 
Linear regression was used to study the dependency of change in disease activity 
(DAS28) on disease activity at baseline.
Responsiveness was analyzed in three ways 1) the correlation of change in RADAI with 
change in the DAS28, by Pearson’s correlation coefficient, 2) analysis of the ability of the 
RADAI to detect a flare, by the plotting of a receiver operating characteristic (ROC) curve 
(29) and calculation of discriminative ability (area under the curve). The ROC curve 
represents the sensitivity and specificity of a decision (flare or non-flare) for all possible 
cut-off points of an underlying variable (change in RADAI score), 3) with a 
responsiveness statistic, the standardized effect size (SES) [29]. The SES is calculated 
as the difference of the within-group changes of the flare and the non-flare group, divided 
by the pooled standard deviations of change. The SES values for RADAI and DAS28 are 
compared with an approximate z-test [30].
We preferred the use of the DAS28 to test for concurrent validity over the various 
individual indicators of disease activity for the following reasons: 1) the DAS28 has 
shown to be a valid estimator of disease activity [26] and is responsive to improvements 
in disease activity [31]; 2) an index combining 3 items may be a better estimator than 3 
items separately; 3) the statistical problem of multiple testing is avoided and 
interpretation facilitated (3); 4) especially important: for the correlational method, there is 
no need to develop an a priori expectation to the various degrees of correlation that may 
be expected with the various indicators of disease activity individually.
The contribution of the single RADAI items to the change in total RADAI score of the 
flare group is analyzed by the item score change in absolute value, the item 
responsiveness by use of the standardized response mean (SRM) [32], and correlation 
of item score change with total RADAI score change by Cronbach’s alpha. The SRM is 
calculated as the ratio of mean change to the standard deviation of change. Higher 
values indicate a better responsiveness. SRMs are most easily interpreted relative to 
each other, within the same study.
It is unclear whether different responsiveness statistics, such as SRM [32], effect size 
(ES), which is calculated as the ratio of mean change to the standard deviation at 
baseline [33] or the responsiveness statistic proposed by Guyatt, which is calculated as 
the ratio of a clinically important difference to the variability in stable subjects [11], will
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lead to comparable results [34] as was suggested [35]. Therefore, we preferred to use 
the SES and the SRM, because they represent change and the same population in both 
nominator and denominator.
The level of statistical significance was set at p=0.05 (two-sided). Data were stored in a 
MedLog database and analyzed with SAS 6.11 statistical software package.
Results
Flare and non-flare group
Within the 90 days of study duration, 26 (57%) of the 46 patients that were on Collagen 
dropped out. Of the 46 patients on MTX, only 7 (15%) dropped out. No reasons for 
leaving the study protocol, other than a flare of disease activity, were noted. The median 
time-to-flare was 31 days (range 17-88; see Figure 1). At baseline, the flare group did not 
differ significantly in population variables from the patients that continued the study 
successfully, except for disease duration and ANA positivity (see Table 1). The 
distribution of gender did not appear to be significantly different between the flare and 
non-flare group. In addition, there are no statistically significant differences on population 
parameters within gender. Regarding the clinical parameters at baseline (see Table 2), 
there is a significant difference between flare and non-flare group in the pain rating only. 
A high level of DAS28 (31) at baseline was not associated with the later development of 
a flare (Fisher Exact: p=0.69).
Changes within and between groups
At study termination, the non-flare group showed no statistical significant changes from 
baseline in any indicator of disease activity. But all disease activity indicators were 
significantly increased (one sample T-test; p<0.0001) in the flare group. The changes of 
the flare group are significantly larger than the non-flare group (Table 2). Comparably, 
the scores of RADAI and the DAS28 were significantly increased in the flare group, from 
baseline as well as in comparison to the non-flare group. The changes from baseline 
have distributions that are normal or close to normal. To interpret the changes from 
baseline in relation to the median values at baseline, median changes as well as mean 
changes are given. In the flare group, DAS28 at baseline explained 7% of the variance of 
change in DAS28, F test: p=0.012.
The distribution of score changes in RADAI is depicted in Figure 2. There is some 
overlap in score changes between the flare and the non-flare group. That means that a 
part of the patients of both groups share the same amount of change in the RADAI.
61
Responsiveness
At baseline, the RADAI and the DAS28 correlate with r=0.58 (Spearman, p<0.0001). As 
can be seen in the scatter plot (Figure 3), overall, the changes in RADAI are highly 
related with changes in DAS28; r=0.70 (p<0.0001).
The discriminative ability of the RADAI for diagnosing a relevant change (a flare) is 0.87, 
(95% Confidence Interval: 0.78 - 0.95). It is also illustrated by the form of the ROC curve, 
that is extending towards the upper left corner of the graph (Figure 4). The discriminative 
ability of the DAS28 regarding the occurrence of a flare is similar: 0.88 (95% CI: 0.81­
0.95). The SES of the RADAI (2.61 - -0.27)/1.84=1.56 was not significantly different 
(p=0.95) from the SES for the DAS28: (1.19 - -0.07)/0.80=1.57. The responsiveness 
statistics for the several indicators of disease activity are shown in Table 2. Please note 
that "pain” and "patient global assessment” are included in the RADAI and that the 
DAS28 includes ESR and the joint counts.
Contribution of single items
The SRMs of the single RADAI items were lower than the SRM of the total score (see 
Table 3). In absolute values, the items two and three contributed most to the overall 
change in RADAI score. The items one and four have the lowest SRM and the lowest 
correlation with change in all other items. Further, the Cronbach’s alpha of the RADAI 
score is raised most by leaving one of these items out.
Discussion
The results of this post-hoc analysis of data from a randomized double blind clinical trial 
of MTX versus Collagen II provides evidence that the RADAI is sensitive to detect 
relevant increases in disease activity in patients with RA. The occurrence of a flare of 
disease activity was used as an external standard of change and was associated with 
raised values in all disease activity indicators used. Besides the DAS28 and the RADAI, 
these were measures included in the World Health Organization/International League 
Against Rheumatism (WHO/ILAR) core set of endpoints for RA clinical trials [3]. The 
responsiveness, of the RADAI is indicated by 1) the changes in the RADAI are well 
correlated with changes in the DAS28; 2) the discriminative ability of the RADAI and of 
the DAS28, reflected by the area under the ROC curve, are virtually the same. The area 
is significantly different from 0.5, where 0.5 indicates that no information is provided [13];
3) the SES values of the RADAI and the DAS28 are about the same and larger than one. 
Interpretation guidelines are not available, but the SES values we found are quite high in
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comparison with values found elsewhere. Buchbinder et al. [30] reported on SES for 
clinical measures ranging from 0.70 (physician global assessment) to 0.07 (ESR), Vliet 
Vlieland et al. [36] reported values of 0.98 (Ritchie Articular Index) towards 0.30 (duration 
of morning stiffness).
Of the single RADAI items, the first item "global disease activity in the past 6 months” 
and the fourth item "duration of morning stiffness” appeared to be the least responsive. 
However, with a SRM of 0.8 or greater they can be considered to be very sensitive 
measures [32]. However, from the nature of the question, the item about the level of 
disease activity in the past six months cannot be expected to be very responsive, even if 
the impression of the level of past disease activity may be influenced by the disease 
activity currently experienced.
There may be some practical and economical reasons to replace assessments done by 
the physician with patient questionnaires. However, the fact that the RADAI and the 
DAS28 perform similarly well does not mean one automatically can replace the DAS28 
with the RADAI [10]. The DAS28 and the RADAI both aim to measure the same 
underlying construct, arthritic inflammatory activity, but from two different ‘perspectives’ 
[10]. The perspective of the patient is formed by perceptions of symptoms and signs, the 
perspective of the physician by judgment of joint swelling, joint tenderness, and ESR.
One of the reasons that the RADAI performs well towards the DAS28 in this study may 
be the use of a flare as an external standard of change. The RADAI may be a more 
direct measure of this unpleasant experience than the DAS28. On the other hand, the 
DAS28 may reflect the underlying arthritic inflammatory activity more directly [37].
A study limitation is that a flare of disease activity is a large change for RA patients. It is 
possible that e.g. morning stiffness may not be very responsive to smaller but relevant 
changes in disease activity. However, the correlation and scatter plot of RADAI and 
DAS28 changes are indicating that the RADAI may be sensitive for smaller changes as 
well. In future studies, the sensitivity of the RADAI for small but clinically relevant 
changes in disease activity has to be assessed together with its smallest detectable 
difference.
We choose not to stratify our sample into subsamples according to medication, because 
power would be lost. We could find no strong indices that patients who had a flare on 
MTX differed at baseline and in response from patients who had a flare on receiving 
Collagen II (data not shown). It appears that no important bias has been introduced. The
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criterion of a flare was used based on the assumption that the patients had stable 
disease activity at baseline and that improvements were not expected by patients or 
physicians. Indeed, the flare group showed significant increases in all indicators of 
disease activity, whereas the non-flare group showed no changes. A high level of DAS28 
at baseline was not predictive for the development of a flare later on. Further, the amount 
of change in DAS28 was largely independent of the baseline value of DAS28 in the flare 
group. Thus, it is unlikely that patients dropped out due to persistent high disease activity 
instead of a flare, or that patients with high levels of disease activity at baseline could not 
"express” their flare in DAS28.
In contrast to our study, most studies done on responsiveness of measures in RA 
concentrate on treatment effects and an improvement of disease activity is expected. In 
few studies, the responsiveness of questions on patient perceptions of signs and 
symptoms, similar to the RADAI, was studied. In a trial for multidisciplinary treatment in 
RA, the VAS for severity of morning stiffness was more responsive than the VAS for 
morning stiffness duration [36]. Moreover, the morning stiffness severity measure was 
the most responsive of all (core set) endpoint measures used. In a RCT comparing low- 
dose cyclosporine with placebo, morning stiffness (in minutes) and pain (VAS and Likert 
scale) were among the least responsive measures. But the combination of four arthritis 
pain related questions (AIMS-2) appeared to be the only measure more responsive than 
the standard tender joint count [30]. In a trial of several anti-rheumatic drug treatment 
strategies, the physical discomfort measures, pain and well-being, were the most 
responsive for treatment effect at 3 months [39]. In two other studies [8,40], time was 
used as an external standard of change, and some worsening was likely to have 
occurred, but was not clearly dealt with in the results. A similar questionnaire format as 
the RADAI, was tested for agreement on change by computing the ICCs between 
patients and clinicians for changes in scores over a mean 6-month interval. However, the 
changes of the questionnaire were not compared with external indicators for change in 
disease activity, making it uncertain how far clinical relevant changes occurred [8]. In an 
observational 60-week study on 24 RA patients, it was found that physician and patient 
global assessments, pain scores, and the HAQ were more sensitive to change than other 
clinical measures, while laboratory measures were generally less sensitive to change 
[40]. Thus, it appears that the responsiveness of questions about patient perceptions on 
signs and symptoms may, in the least, equal the responsiveness of clinical measures. 
The different findings with morning stiffness may illustrate the importance of the design of
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the question and the scaling. To further increase the responsiveness of the RADAI, the 
morning stiffness item could be changed to measure severity instead of duration [36]. 
The RADAI item on past disease activity could be replaced by a question regarding 
general well-being in the context of the arthritis [41].
In summary, this study provides evidence that the RADAI, a self-assessed Rheumatoid 
Arthritis Disease Activity Index, is sensitive to detect relevant increases in disease 
activity in patients with RA. In future studies the sensitivity of the RADAI has to be 
assessed for small but relevant clinically relevant changes in increasing and decreasing 
disease activity. The RADAI may complement clinical measures in clinical studies, or 
may be used as a proxy for disease activity in epidemiological studies.
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Table 1 Population characteristics.
Non-Flare Flare P-value Total
n= 59 33 92
Male 8 (14%) 8 (24%) 16 (17%)
Female 51 (86%) 25 (76%) 0.20 76 (83%)
Age, years 51 (12) 53 (13) 0.37 52 (13)
Disease Duration, years 7 (3-11) 13 (6-16) 0.0014 9 (4-14)
Body Mass Index, kg/m2 23 (21-25) 23 (21-26) 0.89 23 (21-25)
Use of Steroids, yes 23 (39%) 18 (55%) 0.17 41 (45%)
Use of NSAIDs, yes 49 (83%) 24 (72%) 0.26 73 (79%)
ANA, positive 39 (66%) 30 (91%) 0.011 69 (75%)
RF, positive 49 (83%) 31 (94%) 0.32 80 (88%)
HLA-DRB1 A-D, positive 31 (62%) a 19 (66%) b 0.35 50 (63%)
X-ray, range 0-5 points 2.3 (2.0-3.1) 2.5 (2.1-3.1) 0.27 2.3 (2.1-3.1)
ACR I (n=) 13 (22%) 3 (9%) 16 (17%)
Functional Class II 16 (27%) 12 (36%) 0.26 28 (31%)
III 30 (51%) 18 (55%) 48 (52%)
IV 0
Population characteristics and between-group differences at baseline. Values are counts (column 
percentage), mean (SD) for age, median (interquartile range) for the other variables, that are skewed. P- 
values are concerning between group differences.
ANA = Anti Nuclear Antibodies, RF = Rheumatic factors, HLA-DRB1 A-D = RA associated Human
a  hLeucocyte Antigen alleles, classification according to Weyand [23]. Due to missing values: n=50, n=29
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Table 2 Changes in measures of disease activity




from baseline * 
Non Flare Flare
Mean change 




CRP mg/l 12 (5 -  29) 11 (4 -  25) 0.62 -1 (-5 -  6) +18 (7 -  75) -1.1 (35) + 39 (46) 0.34 0.84 1.03
ESR mm/h 16 (8 -  33) 18 (12 -  25) 0.91 0 (-4 -  6) +10 (4 -  31) 0 (13) +19 (20) 0.38 0.81 1.18
Swollen Joints 0-28 5 (2 -  9) 5 (3 -  10) 0.46 0 (-2 -  1) +3 (0 -  6) -0.3 (3.0) +3.4 (3.8) 0.41 0.78 1.14
Tender Joints 0-28 5 (2 -  8) 6 (2 -  9) 0.54 0 (-2 -  1) +3 (2 -  8) -0.6 (4.5) +4.4 (4.8) 0.61 0.80 1.08
Pain 0-10 3 (2 -  5) 4 (3 -  6) 0.032 0 (-1 -  1) +3 (2 -  5) -0.2 (2.0) +3.3 (2.4) 0.79 a 0.89 1 .67
Patient Global 0-10 3 (2 -  5) 4 (3 -  6) 0.32 0 (-1 -  1) +3 (2 -  5) -0.3 (2.3) +3.1 (2.3) 0.84 a 0.87 1.51
Physician Global 0-10 3 (2 -  4) 3 (3 -  5) 0.23 0 (-1 -  1) +3 (2 -  5) 0 (1.3) +2.0 (1.6) 0.61 0.84 1.46
HAQ 0-3 1.0 (0.4 -  1.5) 1.3 (0.5 -  1.8) 0.38 0 (-0.4 -  0.1) +0.4 (0.2 -  0.7) -0.1 (0.5) +0.47 (0.5) 0.77 0.80 1.16
RADAI 0-10 2.0 (0.8 -  3.7) 2.8 (1.5 -  4.7) 0.082 -0.3 (-0.9 -  0.6) +2.6 (2.0) -0.3 (1.7) +2.6 (2.0) 1.00 0.88 1.57
DAS28 0-9 4.3 (1.4) 4.3 (1.3) 0.89 -0.1 (0.8) +1.2 (0.8) 0.70 0.87 1.56
Measures of disease activity for both groups, at baseline and differences from baseline at the moment of study termination. At baseline, values are mean (SD) for 
the
DAS28 and median (interquartile range) for the other variables. Changes from baseline are given in median (IQR) and in mean (SD). A positive sign (+) indicates 
an increase, for all measures this indicates higher disease activity. A negative sign (-) indicates a reduction. P-values are concerning between group differences.
Responsiveness statistics: r = correlation of change with change in RADAI, pa = predictive ability for detecting a flare, SES = standardized effect size.
All (Pearson’s) r are significantly different (p<0.001) from 0, all pa are significantly different (p<0.05) from 0.5. 
a Item correlation with the RADAI, after deletion of that item from the RADAI
* P-values for between-group differences are <0.0001 for median changes (Wilcoxon) and <0.0001 for mean changes (T-test)
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Table 3 Contribution to change
RADAI Items
Mean
change SRM a r
1. In general, how active has your arthritis 
been over the past 6 months?
2.5 (3.2) 0.78 0.84 0.43
2. In terms of joint tenderness and swelling, 
how active is your arthritis today?
2.9 (2.6) 1.12 0.72 0.84
3. How much arthritis pain do you feel today?
4. Were your joints stiff when you woke up today?
If yes, how long did this stiffness last? (no=0; <30 
minutes=1; 30 minutes-1 hour=2; 1-2 hours=3; 2-4 









5. Please indicate the amount of pain you are having today in 
each of the joint areas listed below. (none=0; mild=1; 
moderate=2; severe=3; shoulders, elbows, wrists, fingers, 
hips, knees, ankles, toes.)
1.9 (1.6) 1.19 0.79 0.58
Total RADAI score 2.6 (2.0) 1.31 0.82 --
The change scores of the single RADAI items of the flare group (n=33). Mean (SD) of change, the 
standardized response means (SRM), Cronbach’s alpha (a) of the RADAI without the item, the correlation 
(r) of change in the item with change in all other items.
For the total RADAI score, the Cronbach’s alpha (a) is on all items.
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Figure 1 Number of drop-outs due to flare
d a y s
Figure 2 Distribution of the changes in RADAI
6 Change in














□ Non-flaregroup □ Flaregroup
72
Figure 3 Scatter plot of change in RADAI against change in DAS28
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Figure 4 Receiver Operating Characteristic curve of changes in RADAI
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Abstract
Objective With the help of a measurement-feedback system, the treatment strategy for 
individual RA patients can be adjusted to achieve optimal control of disease activity. The 
main objective was to study whether a measurement-feedback system is effective in 
reducing disease activity in RA patients.
Methods Fourty-eight rheumatologists and 264 patients participated in a controlled 
clinical trial. A 3-months control period was followed by a 12-months period, where 
feedback on disease activity, disability and damage was provided to the rheumatologist. 
Primary outcome measure was the Rheumatoid Arthritis Disease Activity Index (RADAI). 
Results For 62% of the patients, the feedback system was used. DMARD changes 
occurred in 41% of the patients. In patients with high disease activity and feedback use 
(n=70), the RADAI decreased in the feedback period with
-0.27 point per 30 days (p<0.05), as compared to the control period. Patients for which 
the feedback system was used had a better outcome than non-users.
Conclusion Much more training regarding the use of a feedback system and outcome 
measures, as well as the inclusion of explicit treatment guidelines will be necessary to 
increase the clinical use of measurement-feedback and to possibly reduce disease 
activity for a larger number of RA patients.
Introduction
Management of patients with Rheumatoid Arthritis (RA) is challenging and poses specific 
problems. RA has a major impact on function and quality of life. It frequently affects 
patients in their most productive years, and thus, disability results in a major economic 
loss. The cornerstone of RA management is the control of disease activity to alleviate 
pain, maintain function and avoid or slow the rate of joint damage [1]. There is general 
agreement that rheumatoid disease activity should be controlled as soon as possible, as 
completely as possible, and that this control should be maintained for as long as 
possible, consistent with patient safety [2]. Unfortunately, even with the DMARDs and 
"biologic” medications nowadays available, complete remission or optimal control of 
disease activity is not achieved in all patients. Further, for individual patients, it cannot be 
predicted with enough certainty how the course of the disease will develop, if adverse 
events will occur, and if response or remission will be attained. Thus, we are still 
challenged to optimise the management of RA patients.
In 1997 the Swiss Clinical Quality Management in RA (SCQM) was introduced [1]. In the 
Swiss health care system, people have direct access to a rheumatologist, similarly as to
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the general practitioner. The SCQM provides a measurement-feedback system with 
which rheumatologists and their patients can monitor the course of RA disease activity, 
disability and joint damage [3]. Rheumatologists collect standardised clinical, laboratory 
and patient data, and send them to a national co-ordination centre, where the data are 
processed in a computer and a feedback report is returned (Graph 1). With the help of 
the measurement-feedback system, the individual treatment strategy can be adjusted to 
"titrate” RA disease activity until remission is reached or disease activity is optimally 
controlled [1]. Until now, the effectiveness of such a measurement-feedback system in 
RA has not been the subject of research.
The objective of this trial was to study in RA patients, whether a) the measurement- 
feedback system is effective in reducing disease activity, and b) the levels of joint 
damage and disability are consequently maintained or reduced.
Patients and methods
Design
The study was designed as a controlled clinical trial with patients serving as their own 
controls. A 3-months control period, where disease activity was assessed without 
feedback, was followed by a 12-months period, where feedback to the rheumatologist 
was provided. It was hypothesised that the course of disease activity would show a 
reduction in the feedback period as compared to the control period. As a consequence of 
reduced disease activity, it was expected that the development of disability and joint 
damage during the feedback period would stay stable, or even improve.
Recruitment
Rheumatologists from the rheumatology departments of the 5 university hospitals, 6 
regional hospitals and from 2 rheumatological practices throughout Switzerland agreed 
to participate. Patients were recruited during 1997-1998. The rheumatologists asked 
consecutive RA patients (according to the ACR criteria) to participate in self-assessment 
of disease activity for a period of 3 months.
Control period
When the patients agreed to participate, they were sent the Rheumatoid Arthritis Disease 
Activity Index (RADAI) questionnaire on signs and symptoms in RA, once a month, for 
three months [4]. However, when according to the rheumatologist a change in DMARD
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therapy appeared to be necessary, the control period was stopped and the procedure for 
the feedback period started immediately.
Feedback period
The start of the feedback period was scheduled at the fourth month. The patient was 
informed by the rheumatologist about participation in the measurement-feedback system. 
To be included in the study, the patient had to provide written informed consent. In that 
case, the RADAIs from the control period were sent to the co-ordination centre and 
stored for later analysis. At start, the rheumatologists collected the following data: joint 
counts, ESR, current medication use, radiographs of the hands and feet (not older than 6 
months) and patient assessed disease activity (RADAI), disability (Stanford Health 
Assessment Questionnaire; HAQ) [5], socio-demographic variables and comorbidities. 
These data were then sent to the co-ordination centre, where the data were processed 
and a feedback report was returned within 10 days (Graph 1). For the feedback period, 
the rheumatologists were advised to monitor disease activity either with every DMARD 
change or, at the least, every 3 months. For monitoring, disease activity was assessed 
by the rheumatologist (Disease Activity Score; DAS28) [6], and by the patient (RADAI). 
An updated feedback report was sent automatically when the rheumatologist sent those 
data to the co-ordination centre. After 12 months, the last study visit was scheduled, 
which was identical to the starting visit.
Drop-outs
Patients were excluded from the analysis if: 1) A change in DMARD therapy in the 
control period was necessary. To avoid influencing the physicians, the patients were 
excluded after completion of the study. 2) The assessments of the control period were 
missing.
Measurements
The rheumatologists were provided with standardised information on how to perform the 
joint counts and how to handle the questionnaires. At the co-ordination centre, the data 
were checked for completeness and appropriateness before entry. Ambiguities were 
solved by a telephone call.
The DAS28 was calculated from the results of the 28 swollen joint count, the 28 tender 
joint count and ESR [6]. The DAS28 ranges virtually from 0 to 10. A DAS28 below 3.2 is 
regarded as low level disease activity, a DAS28 between 3.2 and 5.1 as moderate, and a
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DAS28 larger than 5.1 as high level disease activity [7]. The RADAI is a 5-item patient 
assessed questionnaire, including arthritis pain, past and current global disease activity, 
duration of morning stiffness and a tender joint list [4]. The RADAI ranges from 0 to 10, 
where higher values are indicative for higher levels of RA disease activity. The RADAI 
has shown to be reliable, valid and responsive for the assessment of disease activity in 
RA [8-10]. The pain item is an 11-numerical rating scale. The disability index of the HAQ 
contains 20 questions about difficulties experienced with 8 activities of daily living, and 4 
questions about the assistance used to perform these [5]. The HAQ is scored from 0-3 
where higher values are indicative for more difficulties when performing activities of daily 
living. Joint damage was scored from radiographs of the hands and feet by readers 
blinded for study allocation, using the Ratingen X-ray score [11]. The scoring of the wrist 
joint is modified by scoring it as a single joint, instead as four joints. The X-ray score 
ranges from 0 to 160, where higher scores are indicative for more and larger erosions of 
the joint surface included.
The patient provided socio-demographic information and information about comorbidities 
on standardised questionnaires [12]. All questionnaires were provided in the language 
preferred by the patient: German, French, or Italian.
Statistical Analysis
Data from intermediate monitoring visits during the feedback period were not the subject 
of analysis, as need-driven visits can overestimate the levels of disease activity during 
this period. Consequently, there are five study time points: 3 in the control period, 2 in 
the feedback period.
The time course of the RADAI scores in the control period was compared with the course 
in the feedback period, using a continuous-by-class regression model with random 
coefficients (intercept and time effect) for patients [13,14]. The procedure thus accounts 
for repeated measurements on the same subjects. To account for the clustering of 
patients in rheumatologists, random coefficients (intercept and time effect) for 
rheumatologists were added.
Changes during the feedback period of disease activity (DAS28), patient perceived pain, 
disability (HAQ) and joint damage (X-ray score) were analysed using paired t-tests and 
95% confidence intervals.
It was hypothesised in advance, that the results could be influenced by the level of 
disease activity in the control period, and whether measurement-feedback was used 
during the feedback period. Accordingly, four subgroups were formed: 1) patients with
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low disease activity in the control period (RADAI score below the median) and no use of 
feedback (the rheumatologist had no feedback reports acquired); low disease activity 
and feedback use (1 or more feedback reports acquired); 3) high disease activity in the 
control period (RADAI score of median or higher) and no use of feedback; 4) high 
disease activity and feedback use. The regression analysis and the analysis of before- 
after differences were repeated as subgroup analysis; differences between subgroups 
(contrasts) were tested using Scheffe’s procedure [15].
To indicate DMARD changes during the feedback period, the medication at start of the 
feedback period was compared with medication at the end. The information from 
intermediate visits was not used, to prevent information bias through underreporting in 
the non-use group.
Data were stored in an Access® 7.0 relational database (Microsoft Corporation, 
Redmond, USA.) and analysed using SAS® 8.1 (SAS Institute Inc. Cary, NC, USA.). The 




Forty-eight rheumatologists enrolled 264 patients; 36 patients were drop-outs (Table 1). 
The RADAI scores and number of dropouts were similar between patients included by 
private practices, regional hospitals or university hospitals. Reasons for dropping out 
were: because of DMARD change in the control period (n=33), and because all RADAIs 
in the control period were missing (n=3). No relevant differences on prognostic and 
outcome variables between dropouts and patients that completed the study were found 
(Table 1). At the end of the feedback period, 38 patients were lost to follow up. These 
patients were not regarded as dropouts.
Response and feedback use
The response in the control period varied between 55% and 65% per time point. At the 
end of the feedback period, 190 (83%) of 228 patients took part in the last study visit. 
During the feedback period, feedback reports were acquired by the rheumatologists for 
142 (62%) patients. Of those, 90 (39%) patients had 1 feedback report, 52 (23%) had 2­
5 feedback reports. Of the remaining 86 (38%) patients, the rheumatologists obtained 
only the report that marked the start of the feedback period.
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Was disease activity stable in the control period?
The group mean (sd) RADAI scores in the control period were 3.6 (2.0), 3.7 (2.1) and 3.7 
(2.1) respectively. According to the regression model, that is correcting for within-person 
dependancies, the RADAI scores did not significantly change over time: ßtime = -0.008 
(95%CI: -0.12 -  0.11); p=0.89 (Table 2).
Was disease activity reduced in the feedback period?
The random time effect for rheumatologists was omitted from the continuous-by-class 
model, because its associated variance did not significantly differ from 0 (not shown). 
The time effect in the feedback period was -0.067 per 30 days (Table 2), which 
corresponds to a mean reduction about 0.8 RADAI points over 12 months. The reduction 
in RADAI in the feedback period was statistically significant. However, the time effect in 
the feedback period was not significantly different from the time effect in the control 
period.
Subgroup analysis
The regression model was subjected to subgroup analysis; the results are shown in the 
lower part of Table 2. The "level of disease activity” in the control period and "feedback 
use” in the feedback period were not associated, (Chi-square; p=0.81). The difference in 
time effects was significant in the subgroup with relatively high disease activity in the 
control period and feedback use in the feedback period (p=0.02). The time effect of that 
subgroup corresponds with a mean reduction in RADAI score over 12 months of more 
than 3 points. Between both subgroups with high disease activity (n=111), the contrast 
between the difference in time effects of the "use” and "non use” group was at the limit of 
statistical significance: p=0.051.
How did disability and joint damage develop?
During the feedback period, disease activity (DAS28) and pain decreased, disability 
(HAQ) did not significantly change, but joint damage (X-ray score) increased (Table 3). 
The subgroup with high disease activity and feedback use, showed significant and 
favourable changes in DAS28, pain and HAQ (Table 3). Their increase in the X-ray score 
was comparably small; it was largest in the subgroup with high disease activity and no 
feedback use. All differences (contrasts) between the subgroups were not statistically 
significant.
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Did changes in medication occur?
The medication changes during the feedback period could only be registered from the 
patients that were not lost to follow-up and had complete medication information (Table
4). At the start of the feedback period, 32 (14%) of 228 patients had no DMARD therapy, 
and 20 (9%) patients had a combination therapy of 2 or 3 DMARDs. More than half of the 
prescriptions (59%) appeared unchanged over the feedback period. Change in DMARD 
therapy was not significantly associated with the level of disease activity (Chi-square, 
p=0.33), or use of the feedback system (Chi-square, p=0.50).
Discussion
According to the results of this study, the use of measurement-feedback was associated 
with a reduction of RA disease activity in the feedback period as compared to the control 
period, in patients with high disease activity. The RADAI reduction of that subgroup 
corresponds to a clinically important difference [10] and was nearly three times larger 
than the subgroup of patients also with high disease activity, but no feedback use. In 
concordance, the subgroup with high disease activity and feedback use showed an 
improvement in the HAQ score and only a small increase in joint damage. In contrast, 
the subgroup of patients with high disease activity and no feedback use, had no 
improvement in the HAQ score, and a progression in joint damage that was twice as 
large. Thus it appears that the measurement-feedback system contributed to a reduction 
of disease activity in RA patients.
However, it is clear that a measurement-feedback system is not an intervention that 
causes health effects, but medication may do so. The assumption of a measurement- 
feedback system for RA is that the system is used to evaluate if disease activity must be 
better controlled, or to ensure that disease activity is still under control. Then it does not 
seem to be adequate that changes in DMARD therapy took place in less than half of the 
patients. Moreover, changes in DMARD therapy were not related to the level of disease 
activity at baseline or to feedback use. As the study was not designed to include 
medication strategy in the analysis, and as it is very difficult to judge the appropriateness 
of specific DMARD management for individual patients, it cannot be concluded that the 
feedback did not influence decision-making. But the most important conclusion that can 
be drawn is that not many changes in DMARD therapy occurred, even in patients with 
high disease activity. Also the use of systematic monitoring with the feedback system 
was much lower than was originally anticipated on. One of the reasons for the
81
suboptimal use of the measurement-feedback system may be that available treatment 
guidelines [16,17] were not explicitely incorporated. It is possible that not all 
rheumatologists regarded suppression of disease activity as an explicit treatment goal. 
Also, prescription habits could be influenced by the, meanwhile discarded, "pyramid 
paradigm” [2,17]. Another reason for the low use of the measurement-feedback in the 
study may be the local health care system, where rheumatologists merely may have a 
consulting role for the General Practitioner and see a part of their RA patients probably 
once yearly. Further, not all rheumatologists are used to outcome measures in clinical 
practice. Outcome measures are often appraised as "soft” data, unfamiliarity and 
difficulties with interpretation may lead to uncertainty if, and how, to use all the 
information [18-21]. But the measurement of RA disease activity and disease 
consequences has improved substantially, and is within the ability of practicing 
rheumatologists [22]. The reasons for use and non-use of the measurement-feedback 
system are currently being studied.
The major advantage of the study design with a control period followed by a 
measurement-feedback ("intervention”) period is that the patients and rheumatologists 
are their own controls, and thus are optimally comparable. An important limitation is that 
it was not possible to blind the participants. However, it was tried to keep the patients 
naïve towards outcome expectancy, and therefore the primary outcome was patient 
assessed. A bias from "knowing to be observed” (Hawthorne effect) may have occurred 
in both the control and feedback periods, and thus may not have introduced differential 
bias. Due to the fact that the rheumatologists were not blinded, prescription behaviour 
can theoretically be biased towards socially desired changes in DMARD therapy. 
However, as the number of patients with changes in DMARD therapy appeared to be 
low, this may not have played an important role.
It must be noticed that the study of such a complex intervention as measurement- 
feedback is quite difficult, mainly because: 1) the intervention is mainly addressed to the 
level of the physician, but important effects are expected on the level of the patient, 2) 
the intervention is indirect, in the sense that it in itself will not influence disease activity, 
3) disease activity is subject to many influencing factors at the same time, e.g. on the 
levels of patient, treatment, treatment tolerance, social and physical surroundings and 
prognostic factors of the disease, 4) the effects on outcome are expected to be relatively 
small, whilst the outcome measures used in RA may not be sensitive enough to detect 
small but relevant changes.
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In primary care, several RCTs were performed on the effectiveness of computerised 
measurement-feedback systems, with or without guidelines, mainly in patients having 
hypertension, diabetes, or anticoagulation need [23-29]. From these studies it appears 
that computerised decision support systems (CDSS) were generally ineffective in 
changing physician performance or health outcomes, probably because the same kind of 
difficulties as mentioned above played a role. In arthritis, we could identify two RCTs on 
measurement-feedback systems, addressing disability [30,31]. Both trials could not find 
any health gain. The studies used feedback at fixed moments in time, thus the feedback 
did not systematically coincide with visits or actual patient needs. It is clearly an 
advantage if relevant information is available at the moment of decision, and decision 
options are clear. This is the case with measurement-feedback on drug dosing, of which 
"titration” of disease activity in RA is an example. A systematic review of computerised 
drug-dosing systems included 5 RCTs regarding out-patient maintenance anticoagulation 
therapy [32], of which one trial provided evidence that quality of initiation and control of 
Warfarin treatment was improved by CDSS in comparison to usual care [33]. It follows 
that it seems justified to conclude that, until now there is no strong evidence of the 
effectiveness of measurement-feedback systems, computerised drug dosing systems, or 
computerised guideline implementation systems in several chronic conditions in primary 
care. However, there is still a strong argument for the adoption of a measurement- 
feedback system, or some other form of CDSS, in RA. As the primary target of RA 
treatment is the control of disease activity [17], the treatment has to be individually 
adjusted depending on the treatment effect and limiting toxicity. For reasons of patient 
care alone, but especially when using expensive therapies, it is most appropriate to 
monitor and document medication use, treatment effects and toxicity in the individual 
[17].
The current study provided limited evidence that a measurement-feedback system is 
effective in RA, but the system was not intensively used. The measurement-feedback 
system should be optimized to facilitate its use in clinical practice and its effectiveness 
should be studied using a carefully designed RCT. For these objectives it should be kept 
in mind that the primary target of measurement-feedback is the rheumatologist, not the 
patient. A much more intensive training regarding the use of a measurement-feedback 
system, the DAS as target measure, and the inclusion of explicit treatment guidelines will 
be necessary to increase the clinical use of measurement-feedback and to possibly 
reduce disease activity for a larger number of patients.
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Table 1 Population characteristics at baseline
Included Dropouts p
Patients, n=(%) 228 36
Female, n= (%) 156 (68%) 32 (89%) 0.01
Age years, mean (sd) 59 (13) 60 (15) 0.81
TS years, median (IQR) 12 (6-18) 9 (4-15) 0.15
TD years, median (IQR) 11 (4-17) 8 (4-14) 0.30
RF +, n= (%) 1 61 (80%) 27 (84%) 0.57
ANA +, n= (%) 73 (38%) 7 (23%) 0.12
Pain, median (IQR) 3 (1-5) 4 (2-6) 0.32
RADAI, mean (sd) 3.5 (2.0) 3.8 (1.8) 0.47
DAS28, mean (sd) 4.1 (1.5) 4.4 (1.2) 0.19
HAQ, median (IQR) 1.0 (0.4-1.8) 1.1 (0.5-1.5) 0.49
X-ray score, median (IQR) 3 (0-12) 1 (0-21) 0.71
Values are mean (sd); median (interquartile-range); number (column percentage). 
TS: time since symptom onset; TD: time since diagnosis; RF+: rheumatic Factor 
positivity; ANA+: Anti Nuclear Antibody positivity. RADAI: Rheumatoid Arthritis 
Disease Activity Index; DAS28: Disease Activity Index; HAQ: Health Assessment 
Questionnaire; X-ray: Ratingen X-ray score.
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Graph 1 An example of the feedback to the rheumatologists.
Feedback Report SCQM
____  DAS ......  R A D A I ------- Xra/(ai:10)
Measure 03.05.00 0Z 08.00 01.10.00 24.10.00 07.12.00 mo2.oi
DAS 6.6 4 6 5.1 4 S 3- i 2.6
ESR 22 10 18 1G 4 2
RADAI 7.0 3.5 4.4 4.4 3.3 2.9
Pain 8 4 5 5 Ü 3
HAQ 2.5 2.0 1.5
X-ray<%) 5 14 11
Predication oa 05.00 0208.00^ 01.10.00 24.10.00 07.12.00 10L02.01
Preciiisolone 10 10 10 10 10 10
Methotrexate 20 .20 20 20 20 20
Salazopyrine 1000 1000 1000
Infliximab 216 216 216
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Control Period Feedback Period Difference 
Time Effect Time Effect 
ß(C) 95%CI ß(F) 95%CI ß(C) -  ß(F) 95%CI
Total 228 3.27 *** (2.91 -  3.63) -0.008 ns (-0.12 -  0.11) -0.067 *** (-0.095 -  -0.039) -0.059 ns (-0.177 -  0.058)
Subgroups
1) Low DA, no use
2) Low DA, use
3) High DA, no use









(1.67 -  2.47) 
(1.75 -  2.40) 
(4.33 -  5.19) 





(-0.24 -  0.17) -0.015 ns (-0.057 -  0.026) 
(-0.25 -  0.22) -0.011 ns (-0.071 -  0.049) 
(-0.21 -  0.20) -0.10 *** (-0.15 -  -0.053) 
(-0.15 -  0.30) -0.19 *** (-0.26 -  -0.12)
0.017 ns (-0.18 -  0.22) 
0.0054 ns (-0.23 -  0.24) 
-0.097 ns (-0.29 -  0.10) 
-0.27 * (-0.49 -  -0.041)
Ns p>0.05; *p<0.05; **p<0.001; ***p<0.0001. RADAI: Rheumatoid Arthritis Disease Activity Index. DA: disease activity. See methods for subgroup definitions.
Table 3 Subgroup analysis of changes in estimators of disease activity, disability and joint damage in the feedback period.
n=
A DAS28 
Mean 95% CI Mean
A Pain A HAQ
95% CI Mean 95% CI
A X-Ray Score 
Mean 95% CI
Total 190 -0.3 *** (-0.5 -  -0.2) -0.6 ** (-1.0 -  -0.3) -0.05 (-0.11 -  0.01) 6.7 *** (4.6 -  8.8)
Subgroups
1) Low DA, no use
2) Low DA, use
3) High DA, no use









(-0.6 -  0.2) 
(-0.6 -  0.005) 
(-1.0 -  0.2) 





(-0.9 -  0.6) 0.05 ** (-0.09 -  0.20) 
(-0.8 -  0.3) -0.01 (-0.10 -  0.08) 
(-2.5 -  -0.3) -0.06 (-0.21 -  0.07) 
(-1.7 -  -0.2) -0.14 * (-0.3 -  -0.04)
6.2 ** (2.8 -  9.7) 
5.5 ** (2.4 -  8.6) 
13.1 * (4.7 -  21.4) 
5.4 * (1.0 -  9.8)
*p<0.05; **p<0.001; ***p<0.0001. DAS28=Disease Activity Score, HAQ=Disability Index of the Health Assessment Questionnaire,
X-ray: Ratingen X-ray score. DA: disease activity. See methods for subgroup definitions.
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Table 4 Changes in DMARD medication at one-year follow-up.
Follow-up Non-missing DMARD changes
Subgroup n= n= No change Dose reduced Dose increased Changed
1) Low DA, no use 38 33 22 (67%) 2 (6%) 5 (1 5%) 4 (12%)
2) Low DA, use 64 60 37 (62%) 8 (13%) 10 (17%) 5 (8%)
3) High DA, no use 30 23 9 (39%) 5 (22%) 5 (22%) 4 (17%)
4) High DA, use 58 53 32 (60%) 5 (10%) 7 (13%) 9 (17%)
Total 190 1 69 100 (59%) 20 (12%) 27 (16%) 22 (13%)
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Objective To study the influence of rheumatologists’ guideline adherence on efficacy 
and toxicity of treatment with methotrexate (MTX) in a 48 week, randomized controlled 
trial of MTX with supplementation of folates or placebo in rheumatoid arthritis.
Methods To reach an optimal dose of MTX, guidelines based on the disease activity 
score (DAS) and the occurrence of adverse events were applied. MTX was started with 
7.5 mg/week and raised every 6 weeks by 2.5 mg/week, until a good response was 
reached or adverse events occurred. The course of the DAS was analyzed using 
generalized estimating equations; the occurrence of adverse events was analyzed with 
survival analysis corrected for time dependency.
Results In 51% of the 411 study patients the guidelines were always followed. In 25% of 
patients, non-adherence lead to lower doses and in 24% to higher doses of MTX than 
the guidelines had proposed. In the adherence group, the reduction of the DAS was 
significantly larger (mean 0.4; p=0.0085) compared with the ‘low dose’ group; the ‘high 
dose’ and adherence groups did not differ (mean -0.07; p=0.64). The dropout due to 
severe adverse events appeared not to be different between the three groups. 
Conclusion The effect of prescribing MTX doses higher than the guidelines proposed 
seemed not to be more beneficial than guideline adherence, whereas the prescription of 
MTX doses lower than the guidelines proposed reduced efficacy without clear beneficial 
effect on toxicity. Guidelines assistive in determining the optimal efficacious MTX or 
DMARD dose may be useful in daily clinical practice.
Introduction
The most important aim in the treatment of rheumatoid arthritis (RA) is the reduction and 
control of rheumatoid inflammation and the prevention of irreversible joint damage [1]. As 
a treatment principle, anti-rheumatic medication should be used in doses that are 
sufficiently high to reduce inflammation, unless limiting toxicity is reached [1]. The anti­
rheumatic drugs nowadays available have the potential to act relatively fast. This gives 
the rheumatologist better opportunities to "titrate” DMARD therapy to get RA disease 
activity under control [2]. However, in practice it may be difficult to find the optimal 
effective anti-rheumatic drug dose for an individual RA patient. An important reason is 
the difficulty in the assessment and the judgement of rheumatoid inflammation. 
Therefore, a combination of standardized systematic evaluation of rheumatoid 
inflammation and guidelines to assist in its judgement may be helpful in the treatment of
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RA patients [3]. Generally, clinical guidelines aim at the improvement of health care. 
However, the question is justified if guidelines can be effective in changing physician 
performance and can eventually lead to improved health outcome [4]. For the case of 
RA, we had the opportunity to study the influence of guideline adherence on outcome in 
a clinical trial [5]. The objective was to study whether rheumatologists’ guideline 
adherence had an influence on efficacy and toxicity of treatment with methotrexate 




The study was performed by post-hoc analysis of the data from a 48-week, multicenter, 
randomized, double blind and placebo controlled trial (RCT), on the effect of 
supplementation of folic or folinic acid on toxicity and efficacy of MTX treatment in RA [5]. 
In the RCT, eligible patients with RA according to the ACR criteria were randomly 
allocated to receive MTX with addition of placebo or folic- or folinic acid. Rheumatology 
units from university and regional hospitals were participating. The same study nurse 
monitored the patients for adverse events every 3 weeks. Every 6 weeks, the patients 
were additionally monitored for effectiveness and visited the treating rheumatologist. In 
case of adverse events, visits could be more frequent. Complete information on patients 
and methods is given in the original publication [5]. The study protocol was approved by 
the ethical committees of all participating hospitals.
Guidelines
MTX was taken once weekly, with a starting dose of 7.5 mg/week and a maximal dose of 
25 mg/week. To realize an optimal dose of MTX in the trial, guidelines for increasing and 
reducing the dose were established. Every 6 weeks, the MTX dose could be increased 
with 2.5 mg/week, until a good response was reached. The standardized response 
criteria were a preliminary version of the EULAR criteria, and compared the actual level 
of the Disease Activity Score (DAS) with the level at start of treatment [6,7]. In the 
presence of adverse events, the MTX dose was decreased (mild adverse events), or the 
use of MTX was temporarily (moderate adverse events) or finally stopped (severe 
adverse events) [5]. The guidelines were applied by a medical study coordinator who 
calculated the DAS and judged efficacy and toxicity based on the results of the 
monitoring. The treating rheumatologist was advised regarding the MTX dose, by phone.
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The treating rheumatologists were allowed to deviate from the dose proposed by the 
guidelines. The MTX dose that was finally prescribed was registered.
Measures
The DAS was calculated using the Ritchie articular index (RAI), a swollen joint count, 
erythrocyte sedimentation rate (ESR) and general health [6]. The RAI was calculated 
according to the grading and accumulation described by Ritchie et al., and ranged from 0
- 78 [8]. The swollen joint count ranged from 0 - 44. General health (GH) and pain were 
rated on 100 mm. visual analogue scales (VAS). Patient- and physician global disease 
activity were rated on scales ranging from 0 (no activity) to 5 (very severe activity). The 
importance of possible adverse events was rated by the patients, and used in the 
calculation of toxicity indices according to Fries and the modification by Felson [9,10].
Outcomes
For this study, the course of the DAS over time was regarded as the primary outcome for 
efficacy. Primary outcome for toxicity was the occurrence of severe adverse events, 
consequently leading to the definitive stop of MTX. Secondary outcomes were the 
reduction in the DAS at 48 weeks, the response at 48 weeks, the time needed to reach a 
good response, the number of observations in good response, trial dropout for any 
reason, and the toxicity indices at 48 weeks.
Guideline adherence
The adherence of the rheumatologists to the guidelines as applied by the study 
coordinator was judged after the study had been completed. Adherence was determined 
from the database, by comparing the prescribed MTX dose with the dose proposed by 
the guidelines. If all MTX prescriptions for an individual patient were in congruence with 
the guidelines, this was determined a case of full adherence (FA). A case of non­
adherence (NA) was determined if one or more decisions were not in agreement with the 
guidelines. In case of non-adherence, the dose deviation from the guidelines was 
calculated. If the dose deviation was positive, the patient had received more MTX than 
the guidelines proposed, then the patient was classified as NA+; if the dose deviation 
was negative the patient was classified as NA-.
Statistical analysis
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Baseline differences between the three adherence groups (FA, NA-, NA+) were analyzed 
with the one-way ANOVA, the Kruskal-Wallis test or the Chi-square test, where 
appropriate. The result of non-adherence on MTX dose was analyzed by testing the 
between-group differences of the cumulative dose of MTX at 48 weeks, using one-way 
ANOVA and contrasts.
The course of the DAS over time was analyzed using a non-linear regression model with 
random coefficients for patient, suited for repeated measurements (generalized 
estimating equations) [11]. Differences between the adherence groups were tested using 
contrasts. The dropout due to severe adverse events was analyzed using survival 
analysis, accounting for the fact that the final adherence status was not known at start of 
the trial [12]. If that would be neglected, it would seem that guideline adherence causes 
early drop-out, while in fact early drop-out may "cause” adherence by preventing from 
committing non-adherence. Differences in drug survival between the adherence groups 
were analyzed using Chi-square tests [12].
The survival analysis was repeated with dropout for any reason (patient wish, protocol 
violation, inefficacy, and severe adverse events). Differences between the three 
adherence groups in DAS reduction and response at 48 weeks, time-to-good-response, 
number of observations in good response, and in the toxicity indices, were analyzed 
using a Chi-square test, one-way ANOVA, or a Kruskal-Wallis test, where appropriate. A 
Bonferroni procedure was applied when comparing the non-adherence groups with the 
full adherence group, by dividing a=0.05 by 2, giving a border of statistical significance of
0.025. The data were analyzed using SAS 8.1 (SAS Institute Inc. Cary, USA).
Results
Guideline Adherence
In 208 (51%) of the 411 patients included in the RCT, all decisions on MTX dosage taken 
by the treating rheumatologist were in agreement with the guidelines as applied by the 
study coordinator. In contrast, in 203 (49%) patients a total of 390 decisions were not in 
agreement with the guidelines. The decisions involved in non-adherence are listed in 
Table 1. The deviations from the guidelines were generally not larger than one dose step 
in the protocol: 2.5 mg/week. As a result, individual patients could have received less 




In Table 2, it is shown that both forms of non-adherence (NA- and NA+) were equally 
divided among the three original treatment arms of the trial. At baseline, differences 
existed in gender (more female in NA+) and disease duration (NA+ shorter). A small and 
non-significant difference appeared in baseline values of the DAS.
MTX Dose
In Graph 1, the deviations of the cumulative MTX dose of both non-adherence groups as 
compared with the adherence group are shown. After week 24, the median cumulative 
dose of the NA- group did not increase as much as in the NA+ and FA groups. At the end 
of the trial, the resulting cumulative MTX dose of the NA- group (median 615 mg) was 
significantly lower (p=0.007) than the cumulative MTX dose of the FA group (median 650 
mg). It can also be seen in Graph 1 that after week 18 the median cumulative MTX dose 
increased in the NA+ group as compared with the FA group. After week 36 this 
difference nearly diminished, by dose increases in the FA group. At week 48, the 
cumulative dose of the NA+ group (median 652.5 mg) was comparable (p=0.93) to the 
FA group (median 650 mg).
Efficacy
In Graph 2, the course of the DAS over time of the three adherence groups is shown. 
There was a small but significant overall difference in the course of the DAS between the 
three groups (p=0.028). When testing contrasts, the reduction of the DAS over time in 
the NA- group was significantly smaller than in the FA group (p=0.0085), whereas the 
course of the DAS of the NA+ group did not differ from the FA group (p=0.64). Correction 
for the level of DAS at baseline did not change the results (not shown). At week 48, the 
decrease in the DAS was larger in the NA+ and FA groups than in the NA- group (Table 
3). Furthermore, the NA+ and FA groups had a larger fraction of good responders, a 
shorter time to good response and a longer time in response, than the NA- group (Table
3).
Toxicity
The dropout due to severe adverse events was not different between NA- group and the 
FA group (Chi-square value=0.19 (1 DF); p>0.60) and between the NA+ and FA groups 
(Chi-square value=0.14 (1 DF); p>0.70). The survival curves are shown in Graph 3. 
When analyzing dropout for any reason, there were again no significant differences
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between the adherence groups (not shown). At 48 weeks, no significant differences in 
the Toxicity Indices appeared between the three adherence groups (Table 3).
Discussion
To our knowledge, this is the first study to demonstrate that adherence to guidelines for 
drug dosing can make a difference in efficacy. The prescription of MTX doses lower than 
the guidelines proposed reduced efficacy and had no clear beneficial effect on toxicity. 
The effect of prescribing higher doses than the guidelines proposed did not seem to be 
more beneficial than full adherence to the guidelines, presumably because the resulting 
cumulative MTX doses were comparable. Thus, in case of guidelines using the DAS for 
MTX dosing in RA, strict adherence to the guidelines appears to be unproblematic and 
moreover, more benificial, than the use of a more loosly "individualized” guideline 
interpretation.
As it was strived to reach optimal guideline adherence in the trial, the differences in MTX 
dose between the three adherence groups were not very large, thus large differences in 
outcome cannot be expected. In the original trial, no significant differences in the course 
of the DAS between the three treatment arms were found [5]. It is important to notice that 
(non-) adherence to the guidelines was equally divided among the three original trial 
arms. Also, the rheumatologists were allowed to deviate from the trial guidelines for MTX 
dosing. Thus, we feel there is no reason to believe that the results are biased due to 
systematic differences in study medication or socially desirable dose registration. The 
most frequent reasons to deviate from the guidelines were on patient wish, to prevent 
possible adverse reactions, or to induce a response sooner. The main limitation of this 
study is, that patients were not randomized to the use of guidelines or not to use 
guidelines. Thus, to be able to answer the question whether clinical guidelines on drug 
dosing indeed can be used to influence physician performance and health outcomes in 
RA patients, it is necessary to use an RCT design, comparing the use of clinical 
guidelines versus "usual care”.
For the use of guidelines, it should be noted that clinical guidelines are not intended to 
replace clinical judgement, and also are not necessarily the only way in which a patient 
can be treated [3]. But the contribution of guidelines to clinical practice is that they 
provide an analytical framework for evaluation and treatment [3]. While it is not difficult to 
subscribe these advantages, multiple barriers can limit physician guideline adherence 
and translation into improved patient outcomes. These barriers can be associated with 
the patient, the guideline, and the practice environment, but can also be physician-bound
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factors as: lack of awareness, lack of familiarity, lack of agreement, lack of self-efficacy, 
lack of outcome expectancy, and inertia of previous practice [13]. These barriers may in 
part explain why to date there is not much evidence to show that guidelines on 
medication prescription can change physician behavior and consequently influence 
health outcomes. Several RCTs have been performed for clinical issues similar to the 
titration of DMARDs for controlling disease activity in RA, especially anti-coagulation 
therapy [14-18], hypertension [19-21] and diabetes [22]. In RA, 2 studies incorporated 
guidelines and monitoring for DMARD dose titration, pointing to the feasibility of a 
combination of monitoring and guidelines on drug dosing [5,23]. In the RCT on the 
effects of the addition of folates or placebo to MTX that was used for this study, 
guidelines using the DAS and explicit response criteria were established to individually 
increase the dose of MTX using a step-up protocol [5]. In a follow-up study of a cohort of 
RA patients on anti-TNFa, the advantages of tailoring anti-TNFa treatment compared to 
the "one size fits all” dosing scheme were demonstrated using a step-down protocol [23]. 
It was shown that the total amount of anti-TNFa given could be reduced by 67%, while 
the level of disease activity was maintained and no patients dropped out due to 
persistent worsening of disease activity.
For use in daily clinical practice, a monitoring system has been developed for RA [24]. It 
allows the systematic registration and (graphical) representation of several parameters of 
disease activity, disability and joint damage, together with medication data. The course of 
disease activity over time can be followed and compared with guidelines or another 
external reference. How the DAS can be used for the titration of DMARD dose in the 
suppression of disease activity in individual patients in daily clinical practice is explained 
by Van Riel [25]. Because the current study was not comparing the use of guidelines 
versus no guidelines, it cannot be said how effective those guidelines would be in clinical 
practice, which should be studied using a RCT design. However, already within the 
framework of the RCT on folate supplementation to MTX [5], a benificial effect of 
guideline adherence appeared. As it can be expected that practice variation in 
prescribing MTX dose in daily clinical practice is much larger than in this study, clinical 
guidelines that are sufficiently adhered to may have a larger influence on efficacy, and 
perhaps on toxicity, in daily clinical practice.
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Table 1 Decisions involved in non adherence to the guidelines.
Non Adherence 
NA - NA + Total
Patients (n) 102 101 203
Decisions (No.) 201 189 390
Specification of decisions
Restart with less than last tolerated dose 6 6
Restart with more than last tolerated dose 3 22 25
No increase, though no good response 132 26 158
No increase, for other reasons 15 17 32
Increased, though good response 1 43 44
Increased with 5.0 mg/week 15 15
Increased with 7.5 mg/week 3 3
Preterm increase 30 45 75
Dose above 25 mg/week 6 6
Decrease below last tolerated dose 8 1 9
Decrease too small 1 1
Decrease by patient initiative 1 1
No temporarily stop, though moderate adverse event 6 6
No decrease, though mild adverse event 3 3 6
Unjustified temporarily stop 2 2
NA - : Patients with a cumulative MTX dose at the end of the trial period that was lower than the guidelines 
proposed; NA + : Patients with a cumulative MTX dose at the end of the trial period that was higher than 
the guidelines proposed. No. : Number.
Table 2 Population characteristics at baseline.
Non Adherence Adherence
NA - NA + FA p Total
N 102 101 208 41 1
MTX + folinic acid 41 (40%) 35 (35%) 65 (31%) 141 (34%)
MTX + folic acid 28 (27%) 31 (31%) 74 (36%) 0.53 133 (32%)
MTX + placebo 33 (32%) 35 (35%) 69 (33%) 137 (33%)
Female (n) 62 (61%) 75 (74%) 153 (74%) 0.04 290 (71%)
RF+ (n) 85 (88%) 78 (80%) 155 (78%) 0.17 318 (77%)
Age (Years) 57 (14) 53 (14) 58 (11) 0.07 56 (13)
Disease duration (Mt.) 47 (12-132) 27 (12-72) 51 (12-130) 0.04 45 (12-117)
Disease Activity Score 4.7 (1.3) 4.9 (0.9) 5.0 (1.1) 0.07 4.9 (1.1)
Ritchie score 17 (10-26) 18 (12-22) 19 (12-28) 0.18 18 (12-26)
Swollen joint count 17 (12-22) 16 (11-21) 17 (12-23) 0.38 17 (12-22)
General health 47 (21) 52 (20) 48 (19) 0.13 49 (20)
Pain score 48 (20) 54 (19) 49 (21) 0.14 50 (20)
Patient global 3 (3-4) 3 (3-3) 3 (3-4) 0.42 3 (3-4)
Physician global 3 (3-4) 3 (3-4) 3 (3-4) 0.79 3 (3-4)
NA - : Patients with a net lower MTX dose than the guidelines proposed; NA + : Patients with a net higher 
MTX dose than the guidelines proposed; FA : Patients with full guideline adherence.
Mt. : months; Patient global: Patient’s global assessment of disease activity; Physician global: Physician’s 
global assessment of disease activity.
Values are counts (column percentage); mean (standard deviation); median (interquartile-range).
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Table 3 Disease activity and toxicity at week 48.
NA - FA NA + p
Contrasts 
NA- vs. FA NA+ vs. FA
N 97 180 98
DAS 3.2 (1.2) 3.2 (1.4) 3.1 (1.1) 0.61 -- --
Decrease in DAS -1.4 (1.2) -1.8 (1.3) -1.8 (1.2) 0.05 0.020 0.80
DAS response none 5 (5%) 16 (8%) 4 (4%)
moderate 57 (56%) 70 (33%) 43 (42%) 0.02 0.011 0.30
good 35 (34%) 92 (44%) 50 (49%)
Time-to-response* (Weeks) 27 (12) 24 (11) 21 (12) 0.0062 0.14 0.031
Observations in response* (No.) 2 (1-4) 4 (2-5) 4 (2-6) 0.0003 0.0003 0.57
Toxicity index Fries 10.9 (4.3-20.4) 8.8 (2.4-19.2) 11.4 (5.3-19.6) 0.30 -- --
Toxicity index Felson 15.4 (13.4-20.7) 10.9 (4.2-22.2) 12.9 (7.2-22.3) 0.47 -- --
NA - : Patients with a net lower MTX dose than the guidelines proposed; NA + : Patients with a net higher MTX dose than 
the guidelines proposed; FA : Patients with full guideline adherence. DAS: Disease Activity Score. No. : Number.
Values are counts (column percentage); mean (standard deviation); median (interquartile-range). * Good or moderate response.
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□ NA- □ NA-t
MTX cumulative dose differences are calculated as differences of the non-adherence groups from the full 
adherence group. Differences are presented as medians.
Graph 2 Course of disease activity (DAS) over time.
Time (weeks)
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Graph 3 Survival analysis, dropout due to severe adverse events.
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Rheumatologists’ opinion on the feasibility of a measurement- 
feedback system in RA -  and the influence of motivation.
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Objective To assess rheumatologists’ opinion about feasibility of a measurement- 
feedback system in RA and to analyse if motivational aspects play a role in valuing and 
use.
Methods A survey sample (N=105) was randomly selected from participants of a 
measurement-feedback system. A survey questionnaire assessed opinions on system 
outcome, structures and processes, motivation and overall satisfaction. Survey results 
are given descriptively, motivation groups were compared.
Results Overall response was 62%. The system is generally perceived to fulfil its aims, 
but the effort to be made is rated less positive. Rheumatologists may have either 
"science/obligation” or "individual patient evaluation” as motivation. Latter 
rheumatologists are more satisfied with the measurement-feedback system, perceived its 
feasibility as better, and made more use of it.
Conclusion Motivation for participating in a measurement-feedback system has a 
significant impact on overall satisfaction and use. Influencing motivation and specific 
reduction of effort might increase overall acceptance.
Introduction
The Swiss Clinical Quality Management in RA (SCQM) is a co-operation of 
Rheumatology departments of all university- and most major hospitals, and 
rheumatologists in private practice throughout Switzerland. Since 1997, the SCQM 
provides rheumatologists with a measurement-feedback system for monitoring the 
disease course of individual RA patients. Using knowledge of the disease course, 
rheumatologists can optimise drug therapy to reduce disease activity and prevent 
progression of joint damage and concurring disability [1]. The accumulated cohort data 
can be used to monitor disease course and burden of disease, and to explore the use of 
different treatment strategies and predictors for outcome [1]. The long-term goal of the 
SCQM is to enable all RA patients to have the optimal treatment, thus minimising the 
burden of the disease to the patient, to his or her social environment and to society [1]. 
Use of the measurement-feedback system is free of charge. Rheumatologists mail 
standardised clinical and laboratory assessments, patient questionnaires, and annually 
X-ray files, to the SCQM co-ordination centre, where the data are processed and stored 
in a database [2]. A comprehensive paper feedback report on the individual patient is 
mailed back to the rheumatologist. It contains a graphical and numerical display of the 
course of disease activity (Disease activity score, Rheumatoid arthritis disease activity
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index, joint counts, pain), disability (Health assessment questionnaire) and joint damage 
(Ratingen X-ray score), laboratory values (e.g. ESR, blood count, alanine 
aminotransferase) and an overview of past and current drug therapy; see [2] for more 
detail. A difference is made between annual assessments and intermediate 
assessments.
The rheumatologists are reminded to perform annual assessments by the co-ordination 
centre. Annual assessments are full assessments including disability and joint damage. 
Reduced intermediate assessments of disease activity and laboratory values are 
performed throughout the year at discretion of the rheumatologist.
For widespread use in clinical practice, a measurement-feedback system should be 
feasible and appreciated as support in daily clinical practice and upon making treatment 
decisions. For studying its efficacy, it is important that compliance to a measurement- 
feedback system is high, as it makes no sense to study the effectiveness of an 
intervention that cannot be adhered to. In an implementation study (submitted) as well as 
in daily practice it was noticed that some rheumatologists did not actively make use of 
the measurement-feedback system, while others intensively used it. To be able to 
improve broader use of the measurement-feedback system, opinion on feasibility was 
assessed among a random sample of rheumatologists with at least some experience 
with the system. In addition, it was analysed whether motivational aspects play a role in 
valuing and use of the measurement-feedback system.
Methods
There were 267 rheumatologists using the measurement-feedback system in 2001. A 
sample (N=105) was drawn with a random number generator, stratified for private 
practice (n=40), regional hospital (n=25), and university hospital (n=40). A numbered 
survey questionnaire was mailed to the sample members early 2002, with a pre­
addressed and prepaid return envelope enclosed. After 4 weeks, a new questionnaire 
was sent to non-responders.
The survey questionnaire was developed to assess opinion on feasibility of the 
measurement-feedback system in 10-15 minutes. An intervention can be thought of as 
feasible, if it sufficiently meets three points: 1) The degree in which the intervention 
meets its stated aims (outcome); 2) The practicability of the structures needed to execute 
the intervention (structure); 3) The acceptability of the way the intervention is dealt with 
(process). These points are covering the three main aspects of clinical quality as 
formulated by Donabedian: outcome, structure and process [3]. There will be an, often
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implicit, trade-off of perceived advantages and drawbacks, leading to an overall valuing 
which can be expressed as satisfaction with the intervention.
The survey questionnaire contained 23 feasibility items with a Likert-scale response 
format 1-6, where 1 is the positive and 6 the negative extreme [4]. Additionally included 
were questions on practice size, motivation to participate in the system, perceived 
advantages and drawbacks and overall satisfaction. The questionnaire was pre-tested 
for apprehension and completeness.
Actual use of the measurement-feedback system in 2001 was determined from the 
SCQM database for every responding rheumatologist, by the number of RA patients 
included in the system, and by the number of them having any intermediate visits.
The survey question about the motivation to participate in the measurement-feedback 
system was qualitatively assessed, and clearly two motivational groups could be formed. 
Wordings like "evaluation”, "long-term follow-up”, "decision support”, etc. were classified 
as describing factors directly related, or "internal”, to the patient-physician relationship. 
Those mentioning "obligatory”, "hospital custom”, "science”, or left the question blank, 
were classified as expressing factors not directly related, or "external”, to the patient- 
physician relationship. Internal and external do not refer to a specific psychological 
construct.
Likert scale item responses were analysed descriptively. Differences between both 
motivation groups were analysed using item response means and the 2-sample t-test, for 
ease of comparison. Difference in overall satisfaction was analysed using Fischer’s exact 
test. Differences in use were analysed using the 2-sample Wilcoxon test.
Results
Response
Of the 105 questionnaires sent, 55 were returned initially and 10 after the reminder. 
Overall response was 62%, with 65% for private practitioners, 80% in regional hospitals, 
and 47% in university hospitals.
Outcome
The responses to the survey items are described in the left-hand part of Table 1.
The majority of respondents (strongly) agreed with the statements, that the 
measurement-feedback is useful in practice, provides a better insight in the disease 
process, and is helpful in monitoring treatment effects and disease course.
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The majority could not fully share the statement that the feedback on disease activity 
influences their treatment decisions. However, many respondents stated that feedback 
makes them feel more certain about treatment decisions taken.
Structure
Most respondents perceived the information as clearly presented and of relevance. But a 
large minority did not fully agree that the information is complete enough for most 
patients to base DMARD treatment decisions on.
The time necessary to perform the assessments of disease activity was generally 
perceived as acceptable. A majority of respondents could not confirm the statement that 
all in all time could be saved later, or that the time spent is in balance with time gained. 
This especially concerns the larger annual assessments, not the intermediate 
assessments of disease activity.
Process
A majority of the respondents stated that they always, or most of the times, showed and 
explained the feedback to the patients, and a majority had a look at it upon receival. 
According to most respondents, they do not regularly assess disease activity between 
the annual assessments. A majority of respondents agreed that performing annual X- 
rays is acceptable for most cases. However, this was the subject of many drawbacks 
(see later). The number of respondents that rated not feeling positive about the effort 
made is considerably large.
Motivation
The rheumatologists’ motivation, described in internal or external factors, makes a 
difference in the rating of overall satisfaction (Table 1). There is a tendency for 
rheumatologists with "internal” motivation, to rate feasibility issues more positive than 
rheumatologists with an "external” motivation (Table 1). E.g. the time spent for an 
intermediate visit was rated more positive by rheumatologists with "internal” motivation. 
Rheumatologists with "internal” motivation also show and explain the feedback report to 
their patients more often.
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Both motivation groups rated the time consumption the same. The majority (66%) stated 
that they used additionally 1-10 minutes when assessing disease activity. For the larger 
annual visits, the rating of the extra time spent ranged from 5-10 minutes to >20 minutes. 
46% stated that the feedback report was received between 10-18 days after the patient 
visit, 33% did not know when it arrived.
Use
The rheumatologists who described an "internal” motivation, included more of their RA 
patients, and performed intermediate assessments in the larger proportion of these 
patients (Table 2). The differences in use could not be explained by a small difference 
between centres, in the hospitals 50% described an "internal” motivation, in private 
practice 70%.
Advantages and drawbacks
Fifty respondents described advantages and drawbacks. The advantages most often 
mentioned were: long-term evaluation/follow-up disease course (n=30); decision 
making/treatment quality (n=25); clear and comprehensive overview (n=25); use of 
objectivable, systematic assessments (n=23); patient and physician communication aid 
(n=17). Drawbacks most often described were: time consumption (n=21); little or no 
consequences for decision support (n=11); inefficient paper bureaucracy (n=9); annual 
X-rays for all (n=8); problems with acquiring patient co-operation (n=7); lag-time of the 
feedback report (n=5); no scientific outcome (n=5); problems with the patient 
questionnaires (n=5); patients are a selection of the RA population (n=4); difficulties with 
the standardised medication documentation (n=4).
Discussion
With the survey a return rate of 62% was reached, which can be considered satisfactory 
for (anonymous) surveys. The low return rate in university hospitals may be caused by 
the large physician turnover in teaching hospitals.
In this sample, the measurement-feedback system was not frequently used, which is not 
in agreement with its purpose to serve as a decision-support to make regular adaptations 
of DMARD therapy. Rheumatologists that participate in the measurement-feedback 
system for the evaluation of their individual RA patients ("internal motivation”) perceived 
the measurement-feedback system as more useful, were more satisfied and less 
bothered by the time consumption, and also made more often use of it. On the contrary,
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if the measurement-feedback was not perceived as useful in treating the own patients 
("external motivation”), feasibility was judged in a more negative way, and use is less. 
Nevertheless, it is supportive that the SCQM measurement-feedback system was 
generally perceived to fulfil its aims, and this was clearly stated in the advantages. 
However, overall satisfaction was not optimal, 70% ("internal”) and 40% ("external”), 
respectively. A satisfaction rate of 80% is not unusual for many situations in health care
[5]. Thus, there is reason to believe that satisfaction should be improved, ideally 
approaching 100%, in all fields of outcome, structure and process. However it can be 
noticed from Table 1 that dissatisfaction concentrates on time costs and decision 
making.
The major advantage of instituting a standardised measurement-feedback system in 
general is that important aspects of disease can be expressed in a more objective way. 
Then, treatment decisions can be based on (semi-) objective data, it is easier to set and 
check treatment targets, treatment results can be compared with trial results, and the 
data may serve as communication aid [6]. However, it should be clear that 
measurement-feedback is meant to be a support for decision making, it adds to, but does 
not replace, clinical thinking and other relevant sources of information. This principle 
should be clearly communicated to users. Major drawbacks of a standardised 
measurement-feedback system are, that it may be felt as a reduction of freedom which 
makes the effort feel as burden, it may make people think that numbers are considered 
more important than patients, and rheumatologists may be afraid for being controlled and 
judged on some abstract treatment result. Further, measurement-feedback systems may 
be quite costly; e.g. an assessment costs the SCQM between 25 and 65 Euro. Even if 
rheumatologists do not pay for the SCQM measurement-feedback system, time means 
also money for a lot of physicians.
The SCQM measurement-feedback system was initially developed in a consensus 
process with key-players among Swiss rheumatologists. From surveying current users, 
several practical points can be derived to be able to increase use of a measurement- 
feedback system for RA. Concerning outcome: Regular workshops on performance of 
assessments and interpretation of scores, and how these can be used for decision 
making, could be provided. Especially for non-laboratory assessments, it can be 
important to raise familiarity, agreement, self-efficacy, and positive outcome expectancy 
[7]. Concerning structure: Easy access to treatment guidelines and a possibility for 
consultancy in difficult cases could be established, apart from the provision of feedback 
alone. Electronic solutions could replace paper ones to reduce effort and to increase
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speed. Patient questionnaires may be collected by a co-ordination centre, in stead of the 
rheumatologists. Concerning process: The performance of X-rays could be changed, e.g. 
less frequent in established disease, and more frequent in early disease. Immediate 
feedback, instead of a time lag of several days, is a great advantage for decision making. 
Then, treatment decisions can be made in presence of the patient, which may enhance 
patient compliance. An easy to understand written and illustrated patient information may 
very well lighten the unpleasant task of persuading patients to join the measurement- 
feedback system. In our opinion, it is of major importance that the aim of a 
measurement-feedback system should clearly be communicated, and that its use for 
evaluating individual RA patients should be stimulated. For the commitment to science, it 
seems important to create "data ownership” and to make regular short communications 
for all data contributors, e.g. in a newsletter.
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Table 1 Survey item responses.
Item
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Outcome 









Time regular visit 
Time saved 
Time in balance 
Process
Explain to patient 
Assess disease activity 
Perform X-rays 
Incorporate feedback 
Effort annual visit 















very positive positive quite positive quite negative negative very negative 
□  □  □  □  □  ■
INT: evaluation as motivation; EXT: obligation or science as motivation
Total INT EXT P-value
2.1 1.7 2.7 0.001
2.4 2.0 3.1 < 0.0001
3.2 2.8 3.8 < 0.0001
2.4 2.0 2.8 0.008
2.0 1.7 2.3 0.02
2.3 2.1 2.5 0.04
2.8 2.4 3.2 0.02
1.7 1.7 1.7 0.88
2.4 2.0 2.9 0.005
3.2 3.1 3.4 0.44
3.2 2.9 3.7 0.02
2.7 2.5 2.9 0.26
3.4 3.5 3.3 0.57
2.3 2.1 2.5 0.37
2.0 1.8 2.4 < 0 .000 '
2.6 2.3 2.8 0.02
2.3 2.2 2.5 0.14
0.006
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% included 75% 11% 0.018
% followed 37% 0% 0.027
Median percentages. P-values from 2-sample Wilcoxon test. 
INT= Motivation by internal factors, EXT = by external factors.
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Chapter 9
Design and analysis of a RCT on the effects of clinical decision 
support on physician performance and health outcome in the
management of RA.
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Abstract
Objective A proposal is made for design and analysis of a randomized controlled trial to 
evaluate the effects of a clinical decision support system on physician performance and 
health outcome in RA.
Methods Sample size calculations for classical and cluster RCT designs were performed 
using a dichotomous and a continuous outcome measure, based on cohort data.
Results A cluster RCT comparing decision support with usual care is the most 
appropriate design. The proportion of patients with rheumatoid inflammation under 
control is the preferred primary outcome measure, for which the Disease Activity Score 
can be used. A sample size of 268 RA patients would be needed to detect a between- 
group difference of 30%. The required sample size is 2.5 times larger than when 
clustering is ignored. The data can be analyzed using multi-level analysis.
Conclusion As cluster RCTs are increasingly being used, awareness should be raised 
of their design and analysis. The methodological considerations in this paper are 
applicable to similar research objectives in Rheumatology.
Introduction
For the management of RA, there is general agreement that rheumatoid inflammation 
should be controlled as soon as possible, as completely as possible and for as long as 
possible, consistent with patient safety [1,2]. When accepting that the goal of RA 
treatment is to reach optimal control of rheumatoid inflammation, it is clear that 
rheumatoid inflammation should continuously be evaluated. Then, the treatment program 
can be adjusted from both perspectives of benefit and harm [3]. The combination of 
systematic evaluation and clinical guidelines could be a valuable decision support in 
optimizing the management of RA [4]. The effects of such decision support should 
preferably be studied using a randomized controlled trial (RCT) design. In this paper, a 
proposal is made for design and analysis of a RCT to evaluate the effects of a clinical 
decision support system on physician performance and health outcome in the 
management of RA. The design of a cluster RCT, the choice of the relevant outcome and 
outcome measure, an approach for statistical analysis, and sample size calculations are 
emphasized. Solutions to prevent bias in this particular design and ethical considerations 
are described.
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Choice of the trial design
In a classical RCT design, patients from single physicians are randomized to receive 
either an experimental or a control intervention, while patients and physicians are blind 
for treatment allocation. A cluster RCT design is appropriate when interventions, like 
guidelines or decision support, are primarily directed to the physicians instead of the 
patients. In that case, the physicians cannot be blinded. To avoid contamination, it is the 
physicians or practices that are randomized, and all their study patients (the cluster) will 
receive the same intervention [5]. Then, it is not appropriate anymore to regard patients 
as independent. The degree of dependency of patients in clusters is indicated by the 
height of the intracluster correlation coefficient (ICC), an ICC equal to zero indicates 
independency. The higher the ICC, the less ‘unique’ information is contributed by the 
single patient and the more the power of the study is reduced. Therefore, it is necessary 
to correct for the effect of clustering in sample size calculations and analysis [6,7].
Choice of the relevant outcome
Decision support, such as guidelines, aims to persuade physicians to change their 
practice behavior [5]. Therefore, when studying decision support it is physician 
performance that is the outcome of interest [5]. Concerning the management of RA, a 
measure of physician performance would thus reflect the adequacy of decisions on 
medication. However, it is difficult to use treatment decisions as an outcome measure, 
because in the management of RA visit frequency is normally not standardized and a 
large number of treatment options are available. As guidelines may alter visit frequency, 
more opportunity for guideline (non-) adherence may be present in one of the trial arms, 
possibly leading to bias. Further, with many treatment options available, judgment of the 
adequacy of treatment decisions is not straightforward, and single visits may not be 
judged in isolation. Since the aim of RA management is to control rheumatoid 
inflammation [1], the level of rheumatoid inflammation or the proportion of patients with 
adequately controlled rheumatoid inflammation could alternatively be used as primary 
outcome. However, it must be noted that these are essentially measures of health 
outcome, and are no direct measures of physician performance. In order to explain 
possible changes in outcome, physician performance should be documented. Secondary 
outcomes that can be considered are toxicity, disability, joint damage, quality of life, 
satisfaction with care, resource use and direct costs.
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Choice of the primary outcome measure
Multiple measures for the clinical assessment of rheumatoid inflammation are available, 
but all are approximating rather than measuring the underlying disease process. The 
disease activity score (DAS28) is a well validated measure, calculated from the results of 
ESR, a swollen joint count, a tender joint count and a general health item [8]. The DAS28 
provides a single index reflecting the level of disease activity. It is a continuous measure 
having a Gaussian distribution, which is an advantage for analysis and power 
calculations. The proportion of patients with adequately controlled disease activity can 
also be derived, e.g. by using a dichotomy with a cut-off point of DAS28 < 3.2 [8], but 
power may be lost by dichotomizing a continuous measure.
Statistical Analysis
The proportion of patients with rheumatoid inflammation under control is a simple 
combination of patients from one rheumatologist into a single summary statistic [5]. 
Then, a two-sample t-test with or without weighting for cluster size [5,9], an adjusted chi- 
square test or computation of an odds ratio with adjusted confidence intervals [5] can be 
carried out. Similarly, the mean change in DAS28 per practice can be used as summary 
statistic, and the two-sample t-test, with or without weighting for cluster size, can be 
carried out [5,9]. The rheumatologist, or practice, was the unit of randomization and is 
also the unit of analysis in these techniques, with the advantage of being relatively 
simple. Alternatively, for dichotomous (low or high DAS28) as well as for continuous 
(change in DAS28) outcomes, multi-level analysis (MLA) [9] can be carried out. MLA is 
not performed on cluster level (rheumatologist or practice) as above, but on individual 
patient level while correcting for the dependency within clusters. MLA is quite a complex 
technique. However, its’ advantage is, as with multiple regression, that it is much easier 
to correct for differences in comparability between trial arms and that e.g. a correction for 
the level of DAS28 at baseline can be made [9].
Sample size when the outcome is dichotomous
Ignoring the clustering of the data, the sample size per trial arm was calculated with the 
usual level for a = 0.05, and a power (1 -  ß) of 0.90, using n = 2(Za/2 + Zß)2 p (1 - p) / (p1
-  p0)2; see [10] for an introduction. Za/2 is the z-value on the standard normal distribution 
corresponding with the chance a to find a difference when in truth none exists; if a=0.05 
(two-sided) then Za/2 =1.96. Zß is the z-value on the standard normal distribution 
corresponding with the chance ß of not finding a difference, when in truth it exists; if
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ß=0.10 then Zß =1.28. The proportion of patients with disease activity under control at the 
end of the trial in experimental group and control group are denoted as p1 and p0, while p 
is the pooled proportion of patients with disease activity under control (p1 + p0)/2.
A sample resembling the target population was taken from an existing cohort [11], and 
consisted of 570 RA patients and 50 rheumatologists (a mean of 11.4 RA patients per 
rheumatologist). The proportion of patients with a DAS28 < 3.2 was 20%. It was 
hypothesized that it was a manageable target to reach low disease activity (DAS28 < 
3.2) in 50% of the RA patients in the experimental group, p1 was then defined to be 0.50 
and p0 as 0.20. Accordingly, the number of patients needed per trial arm was calculated 
as n=53.
It was already indicated that the clustered nature of data reduces power. Therefore, 
sample size has to be increased with a factor known as the design effect (DE). The DE is 
the ratio of sample size with, and sample size without adjustment for clustering, and can 
be calculated using DE = 1+(m-1)p, where m is the average cluster size and p denotes
the ICC. The ICC was calculated using the data from our cohort sample [11]. An ICC of p
2 2 2 2 2 = 0.13 was obtained, calculated as p = G2b - g2w / G2b + (m -  1)g2w , where G2b is the
between cluster variance, g2w is the within cluster variance, and m represents the
average cluster size [9]. The resulting design effect is DE = 1+(11.4 -1) x 0.13 = 2.35.
The sample size needed follows from multiplying the unadjusted sample size with the
DE: 53 x 2.35 = 125 patients per treatment arm. For our cohort sample this would mean
that (125 / 11.4) 11 rheumatologists would be needed. Calculation of DE assumes equal
cluster size. However, usually cluster sizes (practice sizes) are unequal. Then, again
power is lost and the DE calculated is too small [7]. A correction should be applied, for
which the use of minimum variance weights is recommended [7], using
M
DE = mM / I  mi / 1 + (mi -  1)p, 
i=1
where m is the average cluster size, M is the number of clusters, and mi is the observed 
cluster size. This increases the design effect to DE = 2.53, leading to a sample size per 
treatment arm of 134 patients requiring 12 rheumatologists.
Sample size when the outcome is continuous
Again, sample size needed per trial arm was first calculated while ignoring the effect of
2 2 2clustering, with a = 0.05 and 1 -  ß = 0.90 using n = 2(Za/2 + Zß)2 g2 / (m1 -  m0)2. The 
standard deviation for the DAS28 (g=1.48) was again estimated from our cohort sample
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[11]. A relevant difference between mean group changes (m1 -  m0) of 1.2 in the DAS28 
was chosen [8]. As the mean DAS28 in the cohort sample was 4.4, it can be expected 
that with a mean improvement of 1.2 in the intervention group, approximately 50% of 
those patients will have low disease activity (DAS28<3.2) [8]. Accordingly, the number of 
patients per treatment arm was calculated as n=32. The ICC was again calculated from 
our cohort sample, according to p = G2b / (G2b / g2w ) [12], resulting in an ICC=0.25. The 
design effect was calculated as DE = 1+(11.4 -1)0.25 = 3.60. The resulting sample size 
per trial arm is 32 x 3.6 = 115 patients, requiring 11 rheumatologists. The design effect 
adjusted for unequal cluster size was calculated as DE = 3.79 [7]. The sample size has 
to be increased to 121 patients per trial arm, needing 11 rheumatologists.
Choice of the interventions
An experimental intervention could be a computerized clinical decision support system 
(CDSS), allowing for the systematic evaluation of rheumatoid inflammation and the 
provision of clinical guidelines. A threat for the validity of the study is non-use of the 
CDSS by the rheumatologists, which can especially occur when rheumatologists treat 
only a small number of RA patients. Adherence can be enhanced by raising familiarity 
and agreement [13]. The CDSS must be practical, include feasible measurements, and 
produce immediate and meaningful results. It is important to include a run-in period for 
CDSS use and training in the study.
A control intervention ideally should resemble ‘usual care’. However, it can be difficult to 
control for contamination, as it can easily occur by information in literature, by exchange 
between rheumatologists, or by informed consent procedure.
Recruitment of rheumatologists and patients
The study intervention requires a high degree of participation and willingness to change 
practice style for rheumatologists. The influence of losing clusters, e.g. by recruitment 
failure or by drop out, on power can be large if the number of clusters is small (e.g. 20)
[6]. Thus an appropriate recruitment strategy and adequate selection criteria for 
rheumatologists as well as ongoing motivation by the study management are needed. 
Because rheumatologists will play an important role in patient recruitment, it is important 
to use clear patient selection criteria. If randomization is stratified using patient variables 
(e.g. level of disease activity and disease duration), patient recruitment has to take place 
before randomization. That may also be helpful in the prevention of selection bias,
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because rheumatologists randomized to usual care might be less motivated to recruit 
patients, or might recruit patients with a different profile [14].
Blinding
With complex interventions, such as decision support, that are directed to the physicians 
instead of the patients, it is impossible to keep physicians blind. It is also difficult to keep 
patients blind, but an effort must be made to keep patients naive towards outcome 
expectancy. In concordance with clinical practice, the assessments of disease activity in 
the CDSS trial arm, like the DAS28, can be performed by the unblind rheumatologist. For 
statistical analysis of this kind of RCT however, only assessments can be used that are 
made by an independent blinded assessor, e.g. a nurse practitioner. The assessment 
time frame should be identical for both trial arms.
Follow-up
Disease Modifying Antirheumatic Drugs (DMARDs) are the therapy of choice in RA. For 
the evaluation of the efficacy of DMARDs, a follow-up duration of 12 months is generally 
seen as adequate. Clear reductions in inflammatory activity can be expected within 3-6 
months with the DMARDs now available [2]. The primary outcome of CDSS can 
therefore be analyzed at 6 or 12 months. When the course of disease activity over time is 
also of interest, it is advisable to perform blinded outcome assessments at least every 3 
months.
Ethical considerations
In the proposed cluster RCT, treatment options are randomized and patients are 
individually treated and followed. Then, it is necessary to obtain informed consent by the 
individual patients [15]. Only in the special case that an intervention cannot be targeted 
at an individual but only at the cluster as a whole (e.g. special medical education) while 
outcome is on practice level (e.g. number of adequate referrals), consent may be 
obtained only from the person responsible for the cluster’s well being (e.g. a 
rheumatologist) [15].
Discussion
A cluster RCT is the most appropriate design for studying the effects of CDSS in the 
management of RA. Using the proportion of patients with a DAS28 < 3.2 as outcome, it 
was estimated that a sample of 268 RA patients and 24 rheumatologists would be
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needed, which is 2.5 times larger than when the clustering effect is ignored. Multilevel 
Analysis (MLA) may be a useful approach for statistical analysis.
Generally when studying decision support, such as guidelines, it is not necessary to 
study the effect on health [5]. If included guidelines are based on sound evidence, it is 
already known that targeted behavior will be beneficial [5]. As an example, ‘efficacy’ of 
guidelines to improve folate supplementation in addition to MTX can be evaluated by 
simply counting the number of correct prescriptions. In case of CDSS in RA, physician 
performance is more difficult to measure. Therefore, the proportion of patients with low 
disease activity (DAS28 < 3.2) was proposed to approximate physician performance. 
However, as there is no ‘gold standard’ to measure RA disease activity, other outcomes 
can be considered, e.g. the proportion of patients in remission, the proportion of 
responders, change in disease activity, or time-integrated disease activity. Further, 
depending on the target population, other relevant differences and distributions may be 
chosen in the formulas for power calculation, leading to other sample size estimations. 
Also, the magnitude of the ICC may be different for other populations and measures. 
Most of the times power is lost when dichotomizing a continuous measure, and the 
estimated sample size will therefore increase. In our example, no large difference in 
sample size between use of the DAS28 as a continuous measure or as a dichotomy 
appeared. However, when initially clustering was ignored, the required sample sizes 
(n=32 versus n=53) showed that indeed power was lost when dichotomizing the 
continuous DAS28. The estimated sample sizes became more similar when corrected for 
the design effect, due to differences in the height of the observed ICC’s.
In the past, consequences of clustered data have largely been ignored in clinical studies, 
and as a result, many published studies are underpowered [16]. Currently, cluster RCTs 
are increasingly being used, especially in public health- and general practice research. 
Also in Rheumatology, practitioners and researchers should be aware of the 
consequences of clustering for trial design and analysis. The methodological 
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The last decade, important developments in the management of reumatoid arthritis (RA) 
occurred. It was recognised that RA should be treated as early as possible with 
DMARDs, more effective treatment options became available, and progress was made in 
the assessment of treatment effects.
To support the management of RA, the Swiss Clinical Quality Management in 
Rheumatoid Arthritis (SCQM) was established. Core activity of the SCQM is to provide 
rheumatologists with a measurement-feedback system to monitor the course of RA. 
Using the feedback, drug therapy can be optimised to reduce disease activity, leading to 
prevention of joint damage and concurring disability.
The main subject of this thesis is to study if measurement-feedback, or decision support, 
is effective in the management of RA.
Chapter 2
There is general agreement that rheumatoid inflammation should be controlled as soon 
as possible, as completely as possible, and that control should be maintained for as long 
as possible, consistent with patient safety.
Accepting that the goal of treatment is to reach optimal control of rheumatoid 
inflammation, it is clear that rheumatoid inflammation should regularly be evaluated. 
However, regular and systematic monitoring of rheumatoid inflammation is not commonly 
used in daily clinical practice. Beneath practical barriers, the most important barrier is: 
how does a clinician know when rheumatoid inflammation is optimally controlled or in 
remission? What are the criteria to state that inflammatory activity is under control?
There is no gold standard to assess the severity of rheumatoid inflammation, thus it has 
to be estimated. The disease activity score (DAS) and the EULAR response criteria are 
suited to aid in determining and evaluating actual status and change in status, 
particularly when applied to individual RA patients. The reason is, that the EULAR 
response status depends on the absolute level of DAS reached. A low level of DAS over 
time reduces the probability of progression of radiological visible joint damage. How the 
DAS can be used for dose titration is demonstrated in 2 studies in RA, using a step-up 
and a step-down protocol.
It is concluded that, to evaluate if treatment goals are reached and to support 
accomodation of the treatment program, the management of RA patients in daily clinical 
practice should include systematic and regular evaluation of rheumatoid inflammation.
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For determining status and change of individual RA patients in daily clinical practice, core 
set measures and response criteria may be used.
Chapter 3
Clinical Quality Management (CQM) in RA aims at reduction of inflammatory activity and 
pain in the short-term, and damage, and consequent disability, in the long-term. 
Rheumatologists are provided with a measurement feedback system with which they can 
regularly follow their patients. Inflammatory activity is measured with the Disease Activity 
Score (DAS28) and the Rheumatoid Arthritis Disease Activity Index Questionnaire 
(RADAI), damage with an X-ray score, disability with the Stanford Health Assessment 
Questionnaire (HAQ). Feedback is used to optimise therapy, which in the short term 
allows the activity of the inflammatory process to be adjusted or "titrated". In the long 
term, the therapy result for the individual patient is monitored by the course of disability 
and damage.
In this chapter, a series of cases is presented to illustrate the usefulness of the CQM 
system in the management of individual RA patients. In Case 1, it is illustrated how 
periods of increased inflammatory activity (flares) present in numerical values and in 
graphs, and how the principle of titration of inflammatory activity works in practice.
Case 2 illustrates that while in mild to moderate RA titration of disease activity towards a 
DAS28 below 3.2 may be achieved using a single DMARD, patients with more severe 
RA may require combination therapy. The next 2 cases illustrate some regularly 
encountered situations requiring individualised interpretation of measures, reminding us 
that treatment of RA is still an art rather than a cookbook approach.
It is concluded that CQM in RA may be helpful when making decisions about adjustment 
of treatment, and to document and communicate these decisions based on quantitative 
data.
Chapter 4
The goal of the Rheumatoid Arthritis Disease Activity Index (RADAI) is to provide an 
easy to use assessment of disease activity. It is a self-administered questionnaire that 
combines five items into a single index: current and past global disease activity, pain, 
morning stiffness and a joint count. In an earlier study, the single index approach of the 
RADAI was found to be valid, basing on the high association of the RADAI with clinically 
assessed joint synovitis and the acute-phase response, the high internal consistency,
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and the loading of the RADAI items on a single factor. However, the sample of RA 
patients used was relatively small (N=55).
A cross-sectional sample of 584 rheumatoid arthritis (RA) outpatients was used to 
assess the internal consistency and the convergent validity of the RADAI. The sample 
represented a wide range of disease duration and levels of disease activity and disability. 
Cronbach's a was 0.87, supporting the summation of the items into a single index. The 
index correlates best with physicians' global assessment of disease activity (r=0.59; 
p<0.0001), HAQ (r=0.55; p<0.0001) and the tender joint count (r=0.55; p<0.0001). 
Correlation with ESR is low (r=0.27; p<0.0001). The RADAI and DAS28 are correlated 
(r=0.53; p<0.0001), but agreement is low.
It is concluded that the RADAI is valid to assess disease activity in RA patients. 
However, the RADAI may not automatically replace other measures of disease activity, 
such as the DAS28.
Chapter 5
In this study, the responsiveness of the Rheumatoid Arthritis Disease Activity Index 
(RADAI) is assessed for increases in disease activity in rheumatoid arthritis (RA) 
patients, with the occurrence of a flare of disease activity as an external standard. 
Post-hoc analysis of data from a randomised double blind controlled trial of MTX versus 
Collagen II (N=92) was used. Responsiveness is analysed by the correlation of change 
in the RADAI with change in the Disease Activity Score (DAS28), and the ability of the 
RADAI to detect a flare by plotting a receiver-operating characteristic (ROC) curve and 
by the standardized effect size (SES). The contribution of the single RADAI items to the 
total change is analysed by absolute values, the standardized response mean (SRM), 
and correlation of item score change with the total RADAI score change.
The changes in the RADAI correlated highly (r=0.70, p<0.0001) with changes in the 
DAS28. The area under the ROC curve was 0.87 (95%CI: 0.78-0.95) for the RADAI, 
which was similar to the DAS28. The SES for the RADAI was 1.56, which was again 
similar to the DAS28. The RADAI items on "past global disease activity” and "morning 
stiffness” contributed the least to the total score change.
This study provides evidence that the RADAI is sensitive to detect relevant increases in 
disease activity in patients with RA. The RADAI may complement clinical measures in 
clinical studies, or may be used as a proxy for disease activity in epidemiological studies.
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Chapter 6
With the help of a measurement-feedback system, the treatment strategy for individual 
RA patients can be adjusted to achieve optimal control of disease activity. The main 
objective was to study whether a measurement-feedback system is effective in reducing 
disease activity in RA patients.
Fourty-eight rheumatologists and 264 patients participated in a controlled clinical trial. A 
3-months control period was followed by a 12-months period, where feedback on 
disease activity, disability and damage was provided to the rheumatologist. Primary 
outcome measure was the Rheumatoid Arthritis Disease Activity Index (RADAI). The 
data were analysed using generalised estimating equations.
For 62% of the patients, the feedback system was used. DMARD changes occurred in 
41% of the patients. In patients with high disease activity and feedback use (n=70), the 
RADAI decreased in the feedback period with -0.27 point per 30 days (p<0.05), as 
compared to the control period. Patients for which the feedback system was used had a 
better outcome than non-users.
Much more training regarding the use of a feedback system and outcome measures, as 
well as the inclusion of explicit treatment guidelines will be necessary to increase the 
clinical use of measurement-feedback and to possibly reduce disease activity for a larger 
number of RA patients.
Chapter 7
The objective was to study the influence of rheumatologists’ guideline adherence on 
efficacy and toxicity in a 48 week, randomized controlled trial of methotrexate (MTX) with 
supplementation of folates or placebo in rheumatoid arthritis.
To reach an optimal dose of MTX, guidelines based on the disease activity score (DAS) 
and the occurrence of adverse events were applied. MTX was started with 7.5 mg/week 
and was raised every 6 weeks by 2.5 mg/week, until a good response was reached or 
adverse events occurred. Adherence to the guidelines was judged after the study had 
been completed. The course of the DAS was analyzed using generalized estimating 
equations; the occurrence of adverse events was analyzed with survival analysis 
corrected for time dependency.
In 51% of the 411 study patients the guidelines were always followed. In 25% of patients, 
non-adherence lead to lower doses and in 24% to higher doses of MTX than the 
guidelines had proposed. In the adherence group, the reduction of the DAS (mean 0.4; 
p=0.0085) was significantly larger compared with the ‘low dose’ group, the ‘high dose’
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and adherence groups did not differ (mean -0.07; p=0.64). The dropout due to severe 
adverse events appeared not to be different between the three groups.
The effect of prescribing MTX doses higher than the guidelines proposed seemed not to 
be more beneficial than guideline adherence, whereas the prescription of MTX doses 
lower than the guidelines proposed reduced efficacy without clear beneficial effect on 
toxicity. Guidelines assistive in determining the optimal efficacious MTX or DMARD dose 
may be useful in daily clinical practice.
Chapter 8
The objective of this survey was to assess rheumatologists’ opinion about the feasibility 
of a measurement-feedback system in RA, and to analyse if motivational aspects play a 
role in perception and use.
A survey sample (N=105) was randomly selected from participants of a measurement- 
feedback system, stratified for private practice, regional hospital, and university hospital. 
The survey questionnaire assessed opinions on system outcome, structures and 
processes, motivation and overall satisfaction. In addition, it was determined for how 
many RA patients the measurement-feedback system was used last year. Survey results 
are given descriptively, the motivation groups were compared.
The overall response was 62%. The measurement-feedback system is generally 
perceived to fulfil its aims, but the effort to be made is rated less positive. 
Rheumatologists may have either "science/obligation” or "individual patient evaluation” 
as motivation. The latter rheumatologists are more satisfied with the measurement- 
feedback system, perceived its feasibility better, and made more use of it. Important 
practice points for improvement were derived from the users.
It is concluded that motivation for joining a measurement-feedback system has a 
significant impact on overall satisfaction and use. Influencing motivation and specific 
reduction of effort might increase overall acceptance.
Chapter 9
The combination of systematic evaluation and clinical guidelines aiming to control 
rheumatoid inflammation could be a valuable decision support in the management of RA. 
A proposal is made for design and analysis of a randomized controlled trial to evaluate 
the effects of a clinical decision support system on physician performance and health 
outcome in RA.
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Sample size calculations for classical and cluster RCT designs were performed using a 
dichotomous and a continuous outcome measure. Population estimators were based on 
cohort data.
A cluster RCT comparing decision support with usual care is regarded the most 
appropriate design. The proportion of patients with rheumatoid inflammation under 
control is the preferred primary outcome measure, for which the Disease Activity Score 
(DAS28) can be used. A sample size of 268 RA patients and 24 rheumatologists would 
be needed to detect a between-group difference of 30%. The required sample size is 2.5 
times larger than when clustering is ignored. The data can be analyzed using multi-level 
analysis.
As cluster RCTs are increasingly being used, awareness should be raised of their design 
and analysis. The methodological considerations for the example in this paper are 






Reumatoïde artritis (RA) wordt met name gekenmerkt door chronische 
gewrichtsontstekingen, vooral aan beide handen en voeten. Ook andere gewrichten 
kunnen bij de ziekte betrokken raken. De ontstoken gewrichten zijn pijnlijk, gezwollen en 
soms stijf en daardoor lastig te gebruiken. Al in de eerste jaren na het begin van de 
ziekte kunnen de gewrichten onherstelbaar beschadigd raken, waarschijnlijk als gevolg 
van de voortgaande gewrichtsontsteking en een woekering van het gewrichtskapsel. Bij 
veel RA patiënten neemt de gewrichtsbeschadiging in de loop van de tijd toe. De 
beschadigde gewrichten kunnen gaan vervormen en vergroeien, veelal met pijn en 
problemen in het dagelijks functioneren als gevolgen.
De precieze oorzaak van RA is nog onbekend. Het ontstekingsproces wordt vooral 
behandeld met bepaalde anti-reumatische medicijnen, met de familienaam "Disease 
Modifying Antirheumatic Drugs”. Het doel van de behandeling met deze anti-reumatica is 
om het ontstekingsproces zo ver als mogelijk te onderdrukken en het voortgaande 
proces van gewrichtsbeschadiging te vertragen of zelfs te stoppen.
In plaats van behandeling met een enkel anti-reumaticum, worden voor een betere 
werking ook wel verschillende anti-reumatica in combinatie gebruikt. Ook worden vaak 
andere ontstekingsremmers en medicijnen om bijwerkingen te helpen voorkomen 
toegevoegd aan een behandeling met anti-reumatica.
Omdat veel RA patiënten langdurig meerdere medicijnen moeten gebruiken, heeft de 
reumatoloog een belangrijke taak in het instellen van de medicatie. Door regelmatig de 
activiteit van het ontstekingsproces te meten kan de reumatoloog bepalen of de 
medicamenteuze dosis verhoogd zou moeten worden, of dat de dosis weer omlaag kan. 
Bij het instellen van de medicatie speelt het ook een rol dat geprobeerd moet worden om 
geen, of in ieder geval zo min mogelijk, bijwerkingen te veroorzaken.
Het behandelingseffect kan dus op de korte termijn beoordeeld worden aan de hand van 
de ontstekingsactiviteit. Het behandelingseffect op de langere termijn kan beoordeeld 
worden met behulp van het dagelijks functioneren (middels een speciale patiënten 
vragenlijst) en de eventueel ontstane gewrichtsschade (middels röntgenfoto’s van 
handen en voeten). Het systematisch beoordelen van ontstekingsactiviteit, functioneren 
en gewrichtsschade in de behandeling van RA is de laatste jaren meer in zwang geraakt, 
mede vanwege de komst van nieuwe, sneller en beter werkende anti-reumatica. Het 
onderwerp van dit proefschrift is de vraag of de systematische beoordeling van de
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ontstekingsactiviteit en andere ziektegevolgen een waarde heeft in de behandeling van 
RA patiënten door de reumatoloog.
Voor de beoordeling van de ontstekingsactiviteit bij RA is het lastig dat de activiteit van 
het ontstekingsproces in de praktijk niet zeer nauwkeurig gemeten kan worden. Het is 
echter wel mogelijk om de mate van ontstekingsactiviteit af te leiden. De 
ziekteactiviteitsscore (DAS) wordt berekend uit het aantal pijnlijke en gezwollen 
gewrichten, de bloedbezinkingssnelheid en het algemeen welbevinden; een lage DAS 
duidt op een lage ontstekingsactiviteit. De DAS kan daarom gebruikt worden als maat 
om de hoeveelheid anti-reumatica en andere ontstekingsremmers af te stemmen 
(Hoofdstuk 2). Als de DAS regelmatig gemeten wordt, geeft dit ook een goed beeld van 
het verloop van de ziekte.
Er is al enige ervaring opgedaan met het gebruik van een gecomputeriseerd 
evaluatiesysteem waarmee reumatologen het ziekteverloop van RA patiënten kunnen 
volgen (Hoofdstuk 3). Het evaluatiesysteem maakt niet alleen gebruik van de DAS, 
maar ook van patiëntenvragenlijsten over ontstekingsactiviteit (RADAI) en 
functiebeperkingen (HAQ) en metingen van de ontstane gewrichtsschade 
(röntgenfoto’s). De reumatoloog en de patiënt kunnen nu in maat en getal zien hoe hoog 
de ontstekingsactiviteit nu is en hoe hoog zij geweest is. Bovendien kunnen ze als 
behandeldoel een bepaalde mate van lage ontstekingsactiviteit afspreken en na enige 
tijd controleren of dat gehaald is. Een gecomputeriseerd evaluatiesysteem is daarmee 
een hulpmiddel voor het nemen van beslissingen over medicijngebruik, wat niet wil 
zeggen dat het gebruikt kan worden als "kookboek”.
De RADAI patiëntenvragenlijst heeft als doel om op een relatief eenvoudige manier de 
ontstekingsactiviteit te meten zonder dat daar een arts voor nodig is, wat bij de DAS wel 
het geval is. De RADAI werd getest in een onderzoek met 584 RA patiënten (Hoofdstuk
4). De RADAI bleek inderdaad iets te zeggen over de mate van ontstekingsactiviteit: als 
de RADAI laag is, is de DAS ook laag, als de RADAI hoog is, is de DAS ook hoog. Deze 
samenhang van de RADAI bestaat ook met een aantal andere belangrijke maten, als: 
opinie van de arts, het aantal pijnlijke gewrichten en de vragenlijst over 
functiebeperkingen. De RADAI en de DAS zijn echter niet dusdanig identiek dat ze 
elkaar kunnen vervangen.
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Net als de DAS zou de RADAI vragenlijst geschikt moeten zijn om het verloop van de 
ontstekingsactiviteit bij RA patiënten te volgen. Om daar achter te komen werd de 
gevoeligheid voor veranderingen van de RADAI getest (Hoofdstuk 5). Er werd daarbij 
gebruik gemaakt van de gegevens van een eerdere studie, waarin veel RA patiënten een 
acute toename van ontstekingsactiviteit hadden gekregen, ondanks de medicijnen. De 
RADAI en de DAS bleken naderhand beide even goed te zijn geweest in het registreren 
van opvlammende ontstekingsactiviteit.
Theoretisch is het gebruik van een gecomputeriseerd evaluatiesysteem in de 
behandeling van RA patiënten zinvol, het is echter lastig om dat ook te bewijzen.
Van 264 patiënten werd gedurende een controleperiode van 3 maanden de 
ontstekingsactiviteit gemeten met de RADAI, zonder dat de reumatologen de uitslagen 
kenden (Hoofdstuk 6). Na deze 3 maanden kregen de reumatologen 12 maanden de 
beschikking over een gecomputeriseerd evaluatiesysteem. Het evaluatiesysteem bleek 
voor de helft van de patiënten ook daadwerkelijk gebruikt te worden, maar dat hing niet 
samen met de hoogte van de ontstekingsactiviteit. Bij patiënten met een hoge 
ontstekingsactiviteit daalde de RADAI het meest, vooral als de reumatoloog het 
evaluatiesysteem gebruikt had. Toch bleef bij veel patiënten de medicatie onveranderd. 
Om bij een groter aantal RA patiënten de ontstekingsactiviteit te doen dalen, lijkt het 
daarom noodzakelijk om behandelingsrichtlijnen toe te voegen aan een 
evaluatiesysteem.
Om een indruk te krijgen of behandelingsrichtlijnen een invloed hebben op de dosis van 
de voorgeschreven anti-reumatica en daarmee op de ontstekingsactiviteit van RA 
patiënten, is gekeken naar een eerdere studie die gebruik maakte van zowel 
behandelrichtlijnen als de DAS (Hoofdstuk 7). Het leek dat het gebruik van doses die 
hoger waren dan de richtlijnen voorschreven, niet extra veel effect hadden. Maar het 
gebruik van doses die lager waren dan de richtlijnen voorschreven leek nadelig te zijn 
voor het behandeleffect, terwijl er niet minder bijwerkingen veroorzaakt leken te worden. 
Het zou daarom best mogelijk kunnen zijn dat het gebruik van de DAS en van richtlijnen 
voor het bepalen van de dosis van anti-reumatica in de behandeling van RA patiënten 
een voordeel oplevert.
Om de redenen van gebruik en onbruik van een gecomputeriseerd evaluatiesysteem te 
achterhalen zijn 105 reumatologen die zo’n systeem wel eens gebruikt hebben toevallig
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uitgekozen en benaderd met een vragenlijst (Hoofdstuk 8). In het algemeen werd 
bevonden dat het evaluatiesysteem aan zijn doelstelling voldoet, maar dat om diverse 
redenen het systeem niet erg gebruiksvriendelijk is. De reumatologen die aangaven het 
systeem inderdaad vanwege de patiëntenevaluatie te gebruiken, in plaats van "voor de 
wetenschap” of "omdat het bij ons verplicht is”, waren meer tevreden met het 
evaluatiesysteem en maakten er ook meer daadwerkelijk gebruik van. Wellicht kan 
gerichte beïnvloeding van beweegredenen en het verhogen van de 
gebruiksvriendelijkheid het gebruik van een evaluatiesysteem door reumatologen 
vergroten.
De effectiviteit van een evaluatiesysteem in de behandeling van RA patiënten is 
totnogtoe onbewezen. In een nieuwe vergelijkende studie zou gekeken kunnen worden 
of bij de behandeling van RA patiënten het gebruik van een evaluatiesysteem met 
behandelingsrichtlijnen een voordeel oplevert tegenover de gebruikelijke manier van 
behandelen (Hoofdstuk 9). Daarbij is het uitgangspunt dat een evaluatiesysteem zich 
primair richt op de reumatoloog en niet op de patiënt. Daarom worden niet de patiënten 
per toeval verdeeld over de twee behandelingsmogelijkheden ("evaluatiesysteem” of 
"gebruikelijk”), maar zijn het dit keer de reumatologen die per toeval verdeeld worden. 
Alle patiënten van een bepaalde reumatoloog krijgen dus automatisch dezelfde soort 
behandeling. Na verloop van tijd kan er gekeken worden of in de "evaluatiesysteem” 
groep het aantal patiënten met een lage ontstekingsactiviteit groter is dan in de groep 
zonder evaluatiesysteem. Omdat in dit geval de patiënten van een reumatoloog allemaal 
dezelfde soort behandeling krijgen, lijken deze patiënten meer op elkaar en dragen 
daardoor per persoon minder informatie bij. Er zijn dan ook ongeveer 2.5 maal meer 
patiënten nodig dan anders. Ook in de statistische berekeningen van het uiteindelijke 
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